Introduction {#s1}
============

The human heart typically has about 2 billion cardiomyocytes (CMs) ([@bib2]; [@bib28]), which together form the muscle layer of the heart responsible for contraction. The determination of the final number of CMs in the different parts of the heart involves highly coordinated processes of cell fate specification and proliferation during development. Understanding the relative contributions of these processes during the different stages of cardiac morphogenesis, as well as the mechanisms behind them, is one of the long-standing goals of the cardiac development field.

Mammalian heart morphogenesis is best studied in the mouse. Early in mouse development, a bilateral group of cells in the splanchnic mesoderm specifies into cardiac precursor cells (CPCs) ([@bib39]) and forms the first heart field (FHF). Cells of the FHF then extend toward the midline to form a crescent-shaped epithelium, known as the cardiac crescent. Through a series of morphogenetic steps, the cardiac crescent gives rise to a structure called the heart tube ([@bib24]; [@bib47]). CPCs from the secondary heart field (SHF), which are derived from pharyngeal mesoderm, are added to the arterial and venous poles of the heart tube ([@bib5]; [@bib23]; [@bib49]). The FHF is believed to give rise mostly to the left ventricle and parts of the atria, whereas the SHF is believed to give rise mostly to the right ventricle, the outflow tract (OFT) and most of the atria ([@bib5]; [@bib15]; [@bib49]; [@bib57]).

The zebrafish has a simpler heart than that of mouse and humans, containing only two chambers. Nevertheless, the successive phases of CM differentiation during development, as well as their associated genetic pathways, are well conserved between zebrafish and other vertebrates ([@bib44]). Because of the optical clarity and external development of zebrafish embryos, as well as the amenability of zebrafish to genetic manipulation, the zebrafish is an excellent model for the study of cardiac development. In the early stages of zebrafish development, a bilateral group of cells in the anterior lateral plate mesoderm (ALPM) specifies into CPCs, and the region where they reside is termed the heart field (HF) ([@bib13]). In zebrafish, both the FHF and the SHF derive from the ALPM ([@bib31]). As in the mouse, the zebrafish FHF forms the initial heart tube while the SHF elongates the heart tube by adding to its arterial and venous poles. LIM domain transcription factor Islet1 (Isl1) marks a subset of SHF cells ([@bib12]; [@bib52]) that eventually give rise to the inflow tract (IFT) of the atrium of the mature heart. A second set of SHF cells is positive for Islet family member Islet2b (Isl2b) and for latent TGFβ binding protein 3 (Ltbp3). These cells become the CMs that populate the arterial pole of the heart tube and eventually contribute to the OFT of the ventricle in the mature heart ([@bib60]; [@bib51]).

Given that CMs derive from the FHF and SHF cells of the mesoderm, the final CM number in the mature heart depends in part on the specification of mesodermal cells to form CPCs. Nkx2.5, Mef2c, and Hand2 are known to promote CM differentiation in zebrafish ([@bib16]; [@bib20]; [@bib29]; [@bib40]). Several signaling pathways have been found to act upstream of some of these transcription factors and to restrict the HF at the rostral and caudal boundaries of the ALPM. At the rostral border of the zebrafish ALPM, Tal1 and Etv2, two transcription factors required for vascular and hematopoietic lineage specification, respectively, repress cardiac specification, thereby reducing the number of CMs in the mature heart ([@bib42]). At the border between the zebrafish ALPM and posterior LPM (PLPM), retinoic acid (RA) signaling from the adjacent forelimb field determines the HF size by restricting the potential differentiation of ALPM cells into heart precursor cells, and thus limits the number of atrial, but not ventricular, cells in the mature heart ([@bib50]).

In addition to molecular pathways regulating the fate decisions of CPCs, the final number of CMs is also determined by signalling pathways that regulate cell proliferation at each stage of cardiac morphogenesis ([@bib12]; [@bib22]; [@bib38]; [@bib47]). One well-characterized signaling pathway is the Hippo signaling pathway, which helps to define the number of cells in a variety of tissues and organs ([@bib59]). In mammalian cells, the active elements of the Hippo pathway include Ste20-like serine/threonine kinase 1 and 2 (Mst1/2, mammalian orthologs of the fruit fly, Hippo), which phosphorylate Large tumour suppressor kinase 1 and 2 (Lats1/2). Phosphorylated Lats1/2 induce the nuclear export of the transcription factor Yes-associated protein 1 (Yap1) and its paralog WW-domain-containing transcription regulator 1 (Wwtr1), also known as Taz. Lats1/2 inhibits the formation of a complex involving Yap1/Wwtr1 and the TEA domain (TEAD) transcription factors by promoting the nuclear export of Yap1/Wwtr1, thereby repressing the expression of downstream target genes ([@bib58]).

In CMs of the mouse heart, Hippo signaling has been implicated in cardiac regeneration after myocardial injury ([@bib30]; [@bib48]; [@bib53]). While *Yap1* and *Wwtr1* double-null mutations in mice are embryonically lethal before the blastula stage ([@bib35]), it has been shown that Nuclear Yap1 induces CM proliferation in the adult and fetal mouse. Furthermore, mice that are depleted of *Lats2*, *Salvador* (*Salv*), or *Mst1/2* using CM-specific Cre drivers exhibit a hypertrophic growth due to an increase in CM proliferation ([@bib59]). Together, these results suggest that Hippo signaling plays a key role in cardiac proliferation in the mouse. However, it is unclear whether Yap1/Wwtr1 are involved in CPC proliferation within the FHF and SHF before the formation of the heart tube. In addition, although Hippo signaling also regulates the expression of genes that are essential for cell specification and differentiation ([@bib58]; [@bib35]), we still do not know whether Hippo signalling plays a role in cardiac cell fate specification.

In the work described here, we sought to examine the role of Hippo signaling in controlling heart cell number beyond its known roles in CM proliferation. Using zebrafish as a model, we examined the role of Hippo signaling at various stages of embryonic development: at the stage when embryos are specifying the HF, at the stage when the heart tube is formed, and in older embryos when heart morphogenesis is largely completed. We demonstrate that Lats1/2-Yap1/Wwtr1-regulated Hippo signaling determines the number of SHF cells in the venous pole that originate from the caudal part of the ALPM. At the molecular level, we show that Yap1/Wwtr1 promote *bone morphogenetic protein-2b* (*bmp2b*) expression and induce the phosphorylation of Smad1/5/9 in both *hand2-* and Isl1-positive cells. Consistently, the absence of *lats1/2* leads to increased *hand2* expression at the boundary between the ALPM and the PLPM and to an increased number of SHF cells in the venous pole. Together, these findings demonstrate that Hippo signaling restricts the number of CPCs located in the venous pole by suppressing Yap1/Wwtr1-dependent Bmp2b expression and *hand2* expression.

Results {#s2}
=======

Lats1/2 are involved in atrial CMs development {#s2-1}
----------------------------------------------

To examine whether Yap1/Wwtr1-dependent transcription determines the CM number during early cardiogenesis, we developed *lats1* and *lats2* knockout (KO) fish using transcription activator-like effector nuclease (TALEN) techniques. Fish with *lats1^ncv107^* and *lats2^ncv108^* alleles lack 10 bp at Exon 2 and 16 bp at Exon 3, respectively, resulting in premature stop codons due to frameshift mutations ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). *lats1^ncv107^* KO fish and *lats2^ncv108^* KO fish were viable with no apparent defect (data not shown). However, almost all the *lats1^ncv107^lats2^ncv108^* double KO (*lats1/2* DKO) larvae died before 15 days post-fertilization (dpf) ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}).

We assessed the effect of Lats1/2 depletion on heart development by counting CM number in the atrium and the ventricle of *lats1/2* mutant larvae which also contained *Tg(myosin heavy chain 6 \[myh6\]:Nuclear localization signal \[Nls\]-tagged tdEosFP);Tg(myosin light polypeptide 7 \[myl7\]:Nls-mCherry)*. These larvae expressed Nls-tdEosFP in the atrial CMs and Nls-mCherry in the whole CMs ([Figure 1A](#fig1){ref-type="fig"}). We found that the number of atrial CMs, but not ventricular CMs, was significantly increased in the *lats1^wt(wild\ type)/\ ncv107^lats2^ncv108^* embryos and in the *lats1^ncv107^lats2^ncv108^* embryos at 74 hr post-fertilization (hpf) ([Figure 1B,C](#fig1){ref-type="fig"} and [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}).

![Knockout of *lats1/2* genes leads to an increase in the number of atrial, but not ventricular CMs during early development.\
(**A**) Confocal 3D-stack images (at 74 hr post fertilization \[hpf\]) of the *Tg*(*myh6:Nls-tdEosFP);Tg(myl7:Nls-mCherry*) embryos with *lats1^wt/wt^lats2^wt/wt^* (top) and *lats1^ncv107^lats2^ncv108^* alleles (bottom). Atrial (A) and ventricular (V) cardiomyocytes (CMs) are EosFP-positive cells and EosFP-negative mCherry-positive cells, respectively. Ventral view, anterior to the top. (**B, C**) Quantitative analyses of the number of atrial (**B**) and ventricular (**C**) CMs of the embryos at 74 hpf with alleles indicated at the bottom. Plus (+) and minus (--) signs indicate the *wt* allele and the allele of *ncv107* or *ncv108* in *lats1* or *lats2* genes, respectively. The confocal 3D-stack images are a set of representative images of eight independent experiments. In the graphs, the total number of larvae examined in the experiment is indicated on the top of columns unless otherwise described. ^\*^p \< 0.05.\
10.7554/eLife.29106.005Figure 1---source data 1.Quantification of atrial ([Figure 1B](#fig1){ref-type="fig"}) and ventricular ([Figure 1C](#fig1){ref-type="fig"}) cardiomyocyte numbers in the embryos with *lats1* and *lats2* mutant alleles.](elife-29106-fig1){#fig1}

To confirm that Hippo signaling is involved in determining the number of CMs, we assessed whether Yap1/Wwtr1-dependent transcription is activated in developing CMs by analyzing two Tead-reporter transgenic lines: first, we used a general Tead reporter line, the *Tg(eef1a1l1:galdb-hTEAD2ΔN-2A-mCherry)*, which expresses human TEAD2 lacking the amino-terminus (1--113 aa) fused with a GAL4 DNA-binding domain under the control of an *eukaryotic translation elongation factor 1 alpha 1, like 1* (*eef1a1l1*) promoter ([@bib14]); second, we generated a CM-specific Tead reporter line, the *Tg(myl7:galdb-hTEAD2ΔN-2A-mCherry)*, which expresses the same construct under the control of the *myl7* promoter. By crossing these fish with *Tg(uas:GFP)* lines, cells with nuclear-translocated Yap1 or Wwtr1 can be identified through their expression of GFP ([@bib14]).

We first showed that the *lats1/2* double knock-out (DKO) affected Hippo signaling using the general Tead reporter. We found that the Yap1/Wwtr1 reporter was active in the *lats1/2* DKO embryos and in the *lats1/2* morphants ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). We next analyzed the activity of the CM reporter at 74 hpf and found that Yap1/Wwtr1-dependent transcription was present in IFT atrial CMs using the CM Tead reporter line ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}).

To identify the stage at which the Tead reporter starts to be active in CMs more precisely, we analyzed the activity of the reporter at an earlier stage. Previous studies have shown that IFT atrial CMs originate from the venous pole of the heart tube ([@bib12]). By examining the progeny of the Tead reporter line crossed with the *Tg(myl7:Nls-mCherry)* line at 24 hpf, we found that the Tead reporter was active in CMs located at the venous pole of the heart tube ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}). Importantly, the *eef1a1l1* and 2A peptide-driven mCherry expression used for screening purposes is very weak compared to mCherry expression driven by the *myl7* promoter and does not affect the intensity analysis. Together, these data suggest that Lats1/2 restrict Yap1/wwtr1-Tead activation during early CM determination.

Lats1/2 determine the number of IFT CMs derived from Isl1-positive SHF cells {#s2-2}
----------------------------------------------------------------------------

Following on from the observation that the Tead reporter is active at 24 hpf in the progeny of SHF cells, we next assessed whether Hippo signaling affects CM number at this stage. Isl1 is a SHF marker because it plays an essential role in the development of CPCs in the SHF, and because its expression delimitates the SHF as early as 24 hpf in zebrafish ([@bib6]). We generated transgenic fish expressing GFP under the control of an *isl1* BAC promoter; the *TgBAC(isl1:GFP)*. The *isl1* transgene recapitulated the endogenous *isl1* expression patterns ([Figure 2---figure supplement 1A,B](#fig2s1){ref-type="fig"}) and expression was found in the IFT of the atrium at four dpf ([Figure 2A,B](#fig2){ref-type="fig"} and [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). *isl1*-promoter-active cells were observed in the endocardium and epicardium at 96 hpf ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}, arrows and arrowheads), but they were absent from the arterial pole, OFT, and ventricular myocardium until four dpf ([Figure 2A,B](#fig2){ref-type="fig"} and [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). To validate our *isl1* reporter further, we made use of Ajuba, a LIM-domain family protein that is known to restrict the number of *isl1*-positive cells in the SHF ([@bib52]). Consistently, *isl1*-promoter-active SHF cells were increased in the *ajuba* morphants ([Figure 2E](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"} and [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). Together, these results suggest that the *TgBAC(isl1:GFP)* line recapitulates *isl1* expression in vivo.

![The Hippo signaling pathway is involved in the formation of Isl1-positive SHF cells in the venous pole.\
(**A**) Single-scan confocal images (at 96 hpf) of the *TgBAC*(*isl1:GFP);Tg(myl7:Nls-mCherry*) embryos. Cells in which both the *isl1* and *myl7* promoters are active are present in the inflow tract (IFT) cells (arrows) but not in the outflow tract (OFT) cells (square bracket). A, atrium; V, ventricle. Ventral view, anterior to the top. (**B**) Quantitative analyses of the number of cells with both *isl1-* and *myl7*-promoter activities in the IFT and the OFT at 96 hpf (n = 10). (**C**) Confocal images (at 26 hpf) of the *TgBAC*(*isl1:GFP);Tg(myl7:Nls-mCherry*) embryos with the *lats1^wt/wt^lats2^wt/wt^* (upper panels) or *lats1^wt/ncv107^lats2^ncv108^* alleles (bottom panels). The boxed regions are enlarged in the panels in the fourth (right) column. Yellow arrows indicate both *isl1-* and *myl7-*promoter activities in cells in the venous pole. White arrowheads indicate cells with *isl1*-promoter activity that are in contact with cells in which there is *myl7*-promoter activity. Confocal 3D-stack images (left two panels) and single-scan images (right two panels). Dorsal view, anterior to the top. (**D, E**) Quantitative analyses of the number of the *isl1*-promoter-active SHF cells in the venous pole of the *lats1^wt/wt^lats2^wt/wt^* embryos, the *lats1^wt/ncv107^lats2^ncv108^* embryos, and the *lats1/2* DKO embryos (**D**), and in embryos shown in [Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"} (**E**). Both cells with *isl1-* and *myl7*-promoter activity and with *isl1*-promoter activity that were in contact cells with *myl7*-promoter activity were counted as SHF cells. The confocal 3D-stack images and single-scan (2 μm) images are a set of representative images of at least four independent experiments. ^\*\*^p \< 0.01.\
10.7554/eLife.29106.009Figure 2---source data 1.The number of *isl1-* and *myl7*-promoter-active cells in IFT and OFT cells at 96 hpf ([Figure 2B](#fig2){ref-type="fig"}), the numbers of *isl1*-promoter-active SHF cells in *lats1/2* mutants ([Figure 2D](#fig2){ref-type="fig"}) and the number of *isl1*-promoter-active SHF cells of embryos at 26 hpf injected with morpholino (MO) and mRNA ([Figure 2E](#fig2){ref-type="fig"}).](elife-29106-fig2){#fig2}

We found that a significant number of Tead reporter-positive CMs were positive for Isl1 in the venous pole ([Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}). Furthermore, the number of both Isl1- and Tead-reporter-positive CMs in the venous pole was significantly increased in the *lats1/2* morphants ([Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"}). Making use of the *TgBAC(isl1:GFP)* line, we next quantified the population of *isl1*-promoter-positive SHF cells in the *lats1/2* DKO embryos at 26 hpf. As expected, the number of *isl1*-promoter-active cells in the venous pole was significantly increased in both *lats1^wt/ncv107^lats2^ncv108^* and *lats1/2* DKO embryos ([Figure 2C,D](#fig2){ref-type="fig"} and [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). Consistent with this, the *isl1*-promoter-active SHF cells were significantly increased in the venous pole of the *lats1/2* morphants ([Figure 2E](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"} and [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). To further confirm the importance of Hippo signaling in the SHF, we analyzed embryos expressing a mCherry-tagged dominant-negative form of Yap1/Wwtr1-Tead-dependent transcription (ytip-mCherry) ([@bib14]) and found that the number of *isl1*-positive cells were significantly decreased in the venous pole ([Figure 2E](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"} and [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). Together, these results demonstrate that Lats1/2-mediated Hippo signaling is involved in reducing the number of SHF-derived CPCs that contribute to the venous pole.

Lats1/2 determine the number of CMs derived from the *hand2*-promoter-active CMs {#s2-3}
--------------------------------------------------------------------------------

To identify the mechanism of action of Hippo signaling, we sought to identify the gene targets of Yap1/Wwtr1 in early CPC differentiation. We examined whether Yap1/Wwtr1 regulate the expression of transcription factors *nkx2.5*, *hand2*, and *gata4*, all of which are essential for early CPC differentiation ([@bib42]). qPCR revealed that *hand2* mRNA expression was significantly upregulated ([Figure 3A](#fig3){ref-type="fig"} and [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}) and that *nkx2.5* and *gata4* mRNAs expression was unaffected in the *lats1/2* morphants ([Figure 3A](#fig3){ref-type="fig"} and [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}). Whole-mount in situ hybridization (WISH) analyses revealed that the *hand2* expression domain, corresponding to the region that gives rise to the heart, was expanded in the *lats1^wt/\ ncv107^lats2^ncv108^* embryos, the *lats1/2* DKO embryos, and the *lats1/2* morphants at 22 hpf ([Figure 3B](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). These data suggest that Lats1/2 determine the number of atrial CMs by inhibiting Yap1/Wwtr1-dependent *hand2* expression.

![Knockout of *lats1/2* results in an increase in the number of cells in the venous pole in which both *myl7* and *hand2* promoters are activated.\
(**A**) Quantitative-PCR analyses of the expression of *nkx2.5*, *hand2*, and *gata4* mRNAs in the whole embryos at 24 hpf showing the effects of MO injection (n = 4). Relative expression of mRNA in the MO-injected morphants to that of the control is shown. (**B**) WISH analyses at 22 hpf of *lats1^wt/wt^lats2^wt/wt^* (n = 7), *lats1^wt/ncv107^lats2^wt/ncv108^* (n = 22), *lats1^wt/ncv107^lats2^ncv108^* (n = 14) and *lats1^ncv107^lats2^ncv108^* (n = 6) embryos using an antisense probe for *hand2*. (**C**) Confocal 3D-stack images (at 26 hpf) of *TgBAC*(*hand2:GFP);Tg(myl7:Nls-mCherry*)-labeled embryos carrying the *lats1^wt/wt^lats2^wt/wt^* (upper panels) or *lats1^ncv107^lats2^ncv108^* allele (bottom panels). GFP images (left), merged GFP and mCherry images (center), and enlarged images of the boxed regions in the center panels (right) are shown. (**D**) Quantitative analysis of the number of cells in which both *hand2* and *myl7* promoters are activated at 26 hpf. (**E**) Confocal 3D-stack images (at 26 hpf) of the *TgBAC*(*hand2:GFP);Tg(myl7:Nls-mCherry*)-labeled embryos containing the *lats1^wt/wt^lats2^wt/wt^* (upper panels, n = 9) or the *lats1^ncv107^lats2^ncv108^* allele (bottom panels, n = 5) immunostained with the anti-Isl1 antibody (anti-Isl1 Ab). Square brackets denote the SHF cells that are Isl1-positive, both *hand2-* and *myl7-*promoter-active cells that are Isl1-positive, and *hand2*-promoter-active cells that are in contact with *myl7*-promoter-active cells. pp indicates the pharyngeal pouch, which expresses the *hand2*-promoter-activated GFP signal. The first, second, third and fourth columns show Isl1 immunostaining, merged images of GFP and Isl1 immunostaining, merged images of Isl1 immunostaining and mCherry labeling, and merged images of all the three (GFP, mCherry, and Isl1 immunostaining), respectively. All of the images are of the dorsal view, anterior to the top. The confocal 3D-stack images and the WISH images are a set of representative images from at least four independent experiments. ^\*\*^p \< 0.01.\
10.7554/eLife.29106.013Figure 3---source data 1.Quantification of the relative mRNAs expression levels ([Figure 3A](#fig3){ref-type="fig"}) and the numbers of both *hand2-* and *myl7*-promoter-active cells ([Figure 3D](#fig3){ref-type="fig"}).](elife-29106-fig3){#fig3}

Overexpression of Hand2 increases the number of SHF-derived CMs in zebrafish ([@bib40]), so we hypothesized that the increased number of CM in *lats1/2* mutants is due to an increase in the number of CPCs in the SHF. We first investigated endogenous *hand2* expression during CM development by analyzing *TgBAC(hand2:GFP)* ([@bib56]), which labels cells in which the *hand2* promoter is activated with GFP, and *Tg(myl7:Nls-mCherry)*, which labels CMs and CM progenitors with nuclear-localized mCherry. At 26 hpf, we found that *hand2-*promoter-active CMs are localized on the anterior side of the growing cardiac tube, corresponding to the venous pole ([Figure 3C](#fig3){ref-type="fig"}). In the *lats1/2* DKO embryos, the number of *hand2-*promoter-active CMs was significantly increased in the venous pole ([Figure 3C,D](#fig3){ref-type="fig"} and [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}). Similarly, the number of *hand2-*promoter-active CMs was increased in the venous pole in the *lats1/2* morphants ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). Furthermore, we found that the population of Isl1-positive SHF cells overlaps with the *hand2-*promoter-active CMs in the very left-rostral end of the cardiac tube ([Figure 3E](#fig3){ref-type="fig"}, brackets). As expected, the population of Isl1-positive SHF cells was increased in the *lats1/2* DKO embryos and in the *lats1/2* morphants ([Figure 3E](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}, brackets). Thus, *hand2* is expressed in differentiated CMs and the *hand2* expression domain contains SHF cells at 26 hpf.

To confirm the involvement of the Hippo pathway in modulating the *hand2* expression domain, we next sought to examine the number of *hand2-promoter*-active CMs in the DKO mutants of *yap1* ([Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}) and *wwtr1* ([@bib33]). As expected, we found that the extension of the embryo along the anterior-posterior axis is severely impaired in *yap1* and *wwtr1* DKO embryos ([Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}) ([@bib25]; [@bib33]). When analyzing the *hand2*-promoter-active cells, we found that their number is greatly reduced ([Figure 3---figure supplement 2C](#fig3s2){ref-type="fig"}). Interestingly, the DKO mutant embryos exhibit cardia bifida, which is also observed in the *hand2* mutant ([@bib55]) ([Figure 3---figure supplement 2C,D](#fig3s2){ref-type="fig"}). Together, these results strongly suggest that the increased CPC number in the *lats1/2* mutants is due to an expansion of the *hand2* expression domain in the SHF.

*hand2*-promoter-active cells at the caudal end of the ALPM migrate toward the venous pole of the cardiac tube {#s2-4}
--------------------------------------------------------------------------------------------------------------

In zebrafish, the origin of venous pole CMs is unknown. In amniotes, the venous pole progenitors are located in the most caudal domain of the ALPM ([@bib1]; [@bib15]). Considering that *hand2* is expressed in the zebrafish LPM ([@bib42]), we hypothesized that *hand2*-promoter-active cells originate from the caudal end of the ALPM. We performed time-lapse imaging from 14 hpf to 26 hpf to investigate whether *hand2*-promoter-active cells of the LPM contribute to the venous pole cells. Cell-tracking analysis revealed that the caudal cells of the ALPM migrate toward the venous pole ([Figure 4A,B](#fig4){ref-type="fig"}, and [Video 1](#video1){ref-type="video"}). ALPM cells move toward the posterior of the cardiac disc by 20 hpf, and subsequently move anterior-laterally toward the venous pole of the cardiac tube by 26 hpf ([Figure 4A--C](#fig4){ref-type="fig"}). These results indicate that *hand2*-promoter-active cells in the venous pole differentiate from the caudal ALPM. To confirm that the caudal ALPM cells are incorporated into the IFT atrial CMs, we sought to perform cell-tracking of *hand2*-promoter-active cells in the caudal region of ALPM cells following photoconversion. To do so, we injected embryos with a plasmid that expresses tdEosFP under the control of *hand2* BAC promoter and photoconverted the cells in the caudal region of both sides of ALPM in these embryos. We found that the photoconverted cells were incorporated into the IFT of the atrium and the OFT of the ventricle ([Figure 4D](#fig4){ref-type="fig"}). This indicates that the cells of the caudal region of both sides of ALPM can become IFT CMs of the atrium.

![Tead-reporter-active cells in the caudal region of the ALPM move to the venous pole.\
(**A**) Time-sequential 3D-rendered confocal images of the *TgBAC*(*hand2:GFP*) embryo from 15.5 hpf to 25.5 hpf (n = 6). Spots of magenta and cyan denote the cells in the caudal part of the left and right ALPM, respectively. Notochord, nc; cardiac disc, cd; cardiac tube, ct. ALPM, cd, and ct are indicated by the blue, yellow, and red broken lines, respectively. (**B**) Tracking of caudal end *hand2*-promoter-active ALPM cells from 14 hpf to 26 hpf. The 3D-rendered confocal image of the *TgBAC*(*hand2:GFP*) embryo at 26 hpf with the track of cells showing color changes from blue to red according to the time after imaging (14 hpf to 26 hpf). (**C**) Schematic illustration of the trajectory patterns of the caudal end ALPM cells from 14 hpf to 26 hpf. Magenta and cyan denote the caudal region of the left and right ALPM, respectively. The cells in the caudal region of the left ALPM (magenta) and the right ALPM (cyan) moved to the venous pole (26 hpf) through the SHF region posterior to the cd (20 hpf). (**D**) Confocal 3D-stack images of the *Tg(myl7:EGFP)* embryo injected with pTol2-*hand2* BAC:tdEosFP at the 12 somite stage (ss) (upper panels) and at 52 hpf (lower panels). Cells from the caudal region of either left ALPM (left four panels, n = 19) or right ALPM (right four panels, n = 18) were photoconverted at 12 ss. The hearts of the photoconverted embryos were imaged at 52 hpf. White squares and white lines indicate the photoconverted area and the outline of the heart, respectively. (**E**) Confocal 3D-stack images (at 12 ss) of the *TgBAC(hand2:GFP);Tg(eef1a1l1:galdb-hTEAD2ΔN-2A-mCherry);Tg(uas:mRFP1*) embryo (n = 6). Tead-reporter-active cells were present in the entire ALPM. Images of the ALPM are in dorsal view, anterior to the top. Images of the heart are in ventral view, anterior to the top. The confocal 3D-stack images are a set of representative images from at least five independent experiments.](elife-29106-fig4){#fig4}

###### *hand2*-promoter-active cells in the caudal region of the ALPM move to the venous pole.

Time-lapse recording of 3D-rendered confocal images of the *TgBAC*(*hand2:GFP*) embryo from 14 hpf (10 ss) to 26 hpf. Note the migration of the caudal region of both the left ALPM (magenta) and the right ALPM (cyan) toward the venous pole of the cardiac tube. Changes in the colors reflect the tracking time (blue, 0 hr; red, 12 hr). Dorsal view, anterior to the top. The time-lapse movie is a set of representative data from six independent experiments. [Video 1](#video1){ref-type="video"} is related to [Figure 4A,B](#fig4){ref-type="fig"}.

10.7554/eLife.29106.016

We next analyzed whether the Tead reporter is active in the *hand2* expression domain of the ALPM. We crossed *TgBAC(hand2:GFP)* lines with general Tead mRFP1 reporter fish. At the 12 somite stage (ss), the Tead*-*reporter-active cells were found in the entire region of the ALPM and overlapped with *hand2-*promoter-active cells in ALPM ([Figure 4E](#fig4){ref-type="fig"}). We further noticed that the Tead reporter was inactive in the rostral region of the PLPM at 12 ss ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). These data suggest that Hippo signaling acts upstream of *hand2* expression in the ALPM and may play a role in determining CM fate in the ALPM.

Hippo signaling regulates the number of SHF cells from the caudal end of the ALPM {#s2-5}
---------------------------------------------------------------------------------

Tead reporter activation in the cells of ALPM prompted us to ask whether Lats1/2-Yap1/Wwtr1 signaling is involved in the proliferation and/or specification of those cells. We examined the proliferation of *isl1*-promoter-active cells using the EdU incorporation assay and found that the number of *isl1-*promoter-active and EdU-positive CMs in the *lats1/2* morphants was comparable to that of controls ([Figure 5A,B](#fig5){ref-type="fig"}). In addition, there was no difference in the number of EdU-positive blood cells and endocardial cells among the two groups (data not shown). Importantly, the timing of EdU incorporation did not affect the results of the proliferation analyses ([Figure 5B](#fig5){ref-type="fig"}), suggesting that the increase in the number of *isl1*-promoter-active SHF cells that resulted from the depletion of Lats1/2 is not caused by cell proliferation after the differentiation of SHF cells from the ALPM.

![Knockout of *lats1/2* leads to an increase in the expression of *hand2* in the boundary between ALPM and PLPM.\
(**A**) Single-scan confocal images (at 96 hpf) of the *TgBAC*(*isl1:GFP);Tg(myl7:Nls-mCherry*) embryos injected with MO and pulsed with EdU from 14 hpf to 26 hpf. Arrows indicate the EdU-incorporated *isl1-* and *myl7*-promoter-active cells in the IFT of the atrium. A, atrium; V, ventricle. Ventral view, anterior to the top. (**B**) The number of EdU-positive *isl1*-promoter-active CMs among the embryos treated with MO. Embryos pulsed with EdU from 14 hpf to 26 hpf (left two columns) and from 20 hpf to 36 hpf (right two columns). (**C**) Schematic illustration of gene expression patterns in the LPM of wildtype (WT) embryos at 10 somite stage (ss). Expression domain of *tal1*, *gata4*, *nkx2.5* and *hand2* are depicted as magenta, yellow, green, and blue, respectively. Dorsal view, anterior to the top. (**D, F, G**) WISH analyses of the embryos at 10 ss using the antisense probes indicated to the left of the panels. (**D, F**) Genotypes are WT (left panels, n = 8 to 18), *lats1/2* DKO (center panels, n = 6 to 13), and *yap1/wwtr1* DKO (right panels, n = 5 to 7). (**D**) Square brackets indicate the gap between *hand2*-positive regions of ALPM and PLPM. (**E**) Quantitative measurement of the distance indicated by the brackets in (**D**) in either the *lats1^wt/wt^lats2^wt/wt^* embryos or the *lats1 ^wt/ncv107^lats2 ^wt/ncv108^* embryos and in either the *lats1^wt/ncv107^lats2^ncv108^* or the *lats1/2* DKO embryos. (**F**) Brackets indicate the *tal1*-positive rostral end of PLPM in the WT. (**G**) Genotypes are WT (left panels, n = 4 to 5) and *lats1/2* DKO (right panels, n = 3 to 4). Dorsal view, anterior to the top. The single-scan (2 μm) confocal images and in situ hybridization (ISH) images are a set of representative images of at least four independent experiments. ^\*\*^p \< 0.01.\
10.7554/eLife.29106.019Figure 5---source data 1.Distance between *hand2*-positive regions of ALPM and PLPM in the control and in the *lats1/2* mutants at 10 ss ([Figure 5E](#fig5){ref-type="fig"}).](elife-29106-fig5){#fig5}

We next tested whether Lats1/2 affect SHF cell specification in the ALPM. At 10 ss, the ALPM and the PLPM can be characterized by the expression of *gata4*, *nkx2.5*, *tal1,* and *hand2. gata4* labels the multipotent myocardial-endothelial-myeloid progenitors of the ALPM; *nkx2.5* is a marker for the ventricular HF; *tal1* marks the hematopoietic cell progenitors; *hand2* marks both the ALPM and the PLPM at 10 ss ([Figure 5C](#fig5){ref-type="fig"}) with a clear gap in between. Interestingly, the gap length of the *lats1^wt/ncv107^lats2^ncv108^* embryos, the *lats1/2* DKO embryos, and the *lats1/2* morphants was significantly shorter than that of wildtype embryos ([Figure 5D,E](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"} and [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). We also found that *tal1* expression was decreased in the rostral end of the PLPM in the *lats1/2* DKO embryos and the *lats1/2* morphants ([Figure 5F](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). A similar analysis in *yap1*/*wwtr1* DKO embryos revealed that *hand2* expression was decreased in both ALPM and PLPM but that the expression of *tal1* was unaffected ([Figure 5D,F](#fig5){ref-type="fig"}). Importantly, the expression of *gata4* and *nkx2.5* was unaffected in *lats1/2* DKO embryos and in *lats1/2* morphants, suggesting that Hippo signaling mainly affects the *hand2* expression domain ([Figure 5G](#fig5){ref-type="fig"}, and [Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). These observations were consistent with the results of qRT-PCR ([Figure 3A](#fig3){ref-type="fig"}).

To confirm the specificity of Hippo action, we examined the expression of *etv2*, which is a marker for blood-vessel progenitors ([@bib42]), and of *hoxb5b*, which is *a* regulatory molecule of RA signaling in the forelimb field ([@bib50]) in the LPM. The expression levels of both *etv2* and *hoxb5b* were comparable between the control and the *lats1/2* morphants ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). Collectively, these results suggest that Lats1/2 negatively regulate Yap1/Wwtr1-dependent differentiation of the LPM into the SHF at the boundary between ALPM and PLPM.

Hippo signaling regulates Bmp-dependent smad activation that determines the number of SHF cells in the venous pole {#s2-6}
------------------------------------------------------------------------------------------------------------------

Signaling mediated by Bone morphogenetic proteins (Bmps) affects various contexts of heart development via Smad phosphorylation-dependent transcriptional activation. Bmp-Smad signaling is known to be essential for SHF formation, FHF-derived CM development, endocardium development and epicardium development ([@bib36]; [@bib41]; [@bib45]; [@bib54]). Yap1 is known to promote *Bmp2b* expression in zebrafish neocortical astrocyte differentiation ([@bib21]) and Bmp2 in mouse endothelial cells ([@bib34]). In the zebrafish embryo, *bmp2b*, but not *bmp4*, is expressed in the LPM ([@bib9]). We hypothesized that Yap1/Wwtr1 are involved in *bmp2b*-dependent signaling during early cardiogenesis. To investigate whether Bmp-Smad signaling is activated in the ALPM, we examined Bmp-dependent transcription using the *Tg(BRE:GFP)* fish embryos, in which the Bmp-responsive element (BRE) drives GFP expression ([@bib10]). At 14 hpf, BRE-positive cells were found in the ALPM ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). Because Bmps induce the phosphorylation of Smad1/5/9 (Smad9 is also known as Smad8) ([@bib19]), we examined the phosphorylation of Smad1/5/9 in the embryos at 14 hpf using immunohistochemistry. The phosphorylated Smad1/5/9-positive cells were found in the ALPM and eyes ([Figure 6A](#fig6){ref-type="fig"}). Phosphorylation of Smad1/5/9 was enhanced in the *lats1/2* DKO embryos and decreased in the *yap1/wwtr1* DKO embryos ([Figure 6A](#fig6){ref-type="fig"}). At 10 ss, *bmp2b* expression was increased in the ALPM and eyes of the *lats1/2* DKO embryos and decreased in the *yap1/wwtr1* DKO embryos ([Figure 6B](#fig6){ref-type="fig"}). Consistently, *bmp2b* mRNA was increased in the *lats1/2* morphants at 10 ss ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). Although we could not detect *bmp4* in the ALPM in the early ss (data not shown), *bmp4* mRNA was increased in the venous pole of the *lats1/2* morphants at 26 hpf ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}). These results suggest that Hippo signaling functions upstream of Bmp-dependent Smad activation in the ALPM during early cardiogenesis.

![The Hippo signaling pathway functions upstream of the Bmp-dependent signal that is necessary for Isl1-positive SHF formation.\
(**A**) Confocal 3D-stack images (at 14 hpf) of embryos immunostained with the anti-pSmad1/5/9 Ab. Blue broken lines indicate the phosphorylated Smad1/5/9-positive cells in the ALPM and eyes. Note that the pSmad1/5/9-positive signals in the ALPM and the eyes are increased and decreased in the embryos of *lats1/2* DKO and *yap1/wwtr1* DKO, respectively (n = 3). Scale bar indicates 60 μm. (**B**) WISH analyses at the 10 somite stage (ss) of WT (n = 9), *lats1/2* DKO (n = 10), and *yap1/wwtr1* DKO (n = 8) embryos, using antisense probe for *bmp2b*. Square brackets indicate the *bmp2b*-positive ALPM. (**C**) Confocal 3D-stack images (at 24 hpf) of the *Tg(BRE:GFP);Tg(myl7:Nls-mCherry*) embryos carrying *lats1^wt/wt^lats2^wt/wt^* (upper panels) and *lats1^wt/ncv107^lats2^ncv108^* alleles (bottom panels). Square brackets highlight the GFP-positive *myl7*-promoter-active cells in the venous pole. Note that the numbers of GFP-positive *myl7*-promoter-active cells are increased in the venous pole. (**D**) Quantitative analyses of the numbers of the both *BRE*-active GFP-positive and *myl7*-promoter-active mCherry-positive cells in the *lats1^wt/wt^lats2^wt/wt^* embryos and in either the *lats1^wt/ncv107^lats2^ncv108^* embryos or the *lats1/2* DKO embryos. (**E**) Confocal 3D-stack images (at 26 hpf) of the *TgBAC*(*isl1:GFP);Tg(myl7:Nls-mCherry*) control embryos (uninjected, upper panels) and embryos injected with 100 pg of *smad7* mRNA (bottom panels). Square brackets indicate the region of *isl1*-promoter-active GFP-positive SHF cells in the venous pole. (**F**) Quantitative analyses of the number of *isl1*-promoter-active SHF cells in the venous pole. Note that overexpression of *smad7* mRNA leads to a decrease in the number of *isl1*-promoter-active SHF cells in the venous pole. (**G**) Confocal 3D-stack images (at 26 hpf) of the *TgBAC*(*isl1:GFP);Tg(myl7:Nls-mCherry*) embryos treated with DMSO (upper panels) or DMH1 (10 μM, lower panels) constructed between 14 hpf and 26 hpf. Square brackets indicate the *isl1*-promoter-active SHF cells in the venous pole. (**H**) Quantitative analyses of the number of *isl1*-promoter-active SHF cells and of the number of both GFP-negative and *myl7*-promoter-active mCherry-positive cells. Note that DMH1 treatment decreases the number of *isl1*-promoter-active SHF cells in the venous pole but does not affect the number of GFP-negative and *myl7*-promoter-active CMs. All images in this figure are in dorsal view, anterior to the top. The confocal 3D-stack images and ISH images are a set of representative images of at least three independent experiments. ^\*\*^p \< 0.01.\
10.7554/eLife.29106.024Figure 6---source data 1.The numbers of BRE-positive cardiomyocytes in *lats1/2* mutants at 24 hpf ([Figure 6D](#fig6){ref-type="fig"}), *isl1*-promoter-active SHF cells with *smad7* mRNA injection ([Figure 6F](#fig6){ref-type="fig"}) and *isl1*-promoter-active SHF cells and GFP-negative CMs with DMH1 treatment ([Figure 6H](#fig6){ref-type="fig"}).](elife-29106-fig6){#fig6}

By analyzing the BRE reporter, we found that the number of Bmp signal-active cells marked by GFP in the venous pole was increased in the *lats1^wt/ncv107^lats2^ncv108^* embryos and/or the *lats1/2* DKO embryos, as well as in the *lats1/2* morphants at 24 hpf ([Figure 6C,D](#fig6){ref-type="fig"}, [Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"} and [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}). Immunohistochemistry revealed that the number of phosphorylated Smad1/5/9-positive and *hand2*-promoter-active cells was also increased at the venous pole of the *lats1/2* morphants at 26 hpf ([Figure 6---figure supplement 2B](#fig6s2){ref-type="fig"}). These results suggest that Yap1/Wwtr1 promote *bmp2b* expression and subsequent Bmp signaling and that Lats1/2 restrict Yap1/Wwtr1-dependent Bmp signaling leading to the formation of the proper venous pole.

We further investigated whether Bmp-Smad activation promotes *hand2* expression. We made use of Smad7, an inhibitory-Smad that blocks Bmp-Smad signaling by interacting with activated Bmp type I receptors and preventing the downstream activation of receptor-regulated Smads ([@bib43]). We first showed that overexpression of *smad7* mRNA caused dorsalization, demonstrating that Smad7 is essential for proper Bmp-Smad signaling, using 200 pg of mRNA ([Figure 6---figure supplement 3A,B](#fig6s3){ref-type="fig"}). Interestingly, the injection of lower concentration of mRNA (100 pg) led to a dorsalization phenotype in only 10% of the injected embryos. Therefore, the remaining embryos without dorsalization phenotype were used to assess heart development ([Figure 6---figure supplement 3A,B](#fig6s3){ref-type="fig"}). The non-dorsalized embryos looked healthy. The injection of *smad7* mRNA did not cause fragmentation of the cells (data not shown), but the embryos exhibited a decreased number of *isl1*-promoter-active cells in the *TgBAC(isl1:GFP);Tg(myl7:Nls-mCherry)* assay ([Figure 6E,F](#fig6){ref-type="fig"} and [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}). Collectively, these results suggest that Bmp-dependent signaling is required for CPC fate determination.

Finally, to confirm the necessity of Bmp-Smad-regulated signaling during SHF formation, we treated the *TgBAC(hand2:GFP);Tg(myl7:Nls-mCherry)* embryos and the *TgBAC(isl1:GFP);Tg(myl7:Nls-mCherry)* embryos with a Bmp inhibitor, DMH1, from 14 hpf to 26 hpf. The efficiency of DMH1 was confirmed by decreased phosphorylation of Smad1/5/9 ([Figure 6---figure supplement 2C](#fig6s2){ref-type="fig"}). The expression of Isl1 and the promoter activity of *hand2* were greatly reduced in the embryos treated with DMH1 ([Figure 6---figure supplement 3C](#fig6s3){ref-type="fig"}). The number of *isl1-*promoter-active SHF cells was decreased in the embryos treated with DMH1, whereas the number of *isl1*-promoter-inactive CMs in the DMH1-treated embryos was comparable to that in the control embryos ([Figure 6G,H](#fig6){ref-type="fig"}, and [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}). We thus conclude that Lats1/2 restrict Yap1/Wwtr1-promoted Bmp2b-dependent signaling, which is required for both *hand2*- and *isl1*-promoter activity during SHF formation.

Discussion {#s3}
==========

Here, we show for the first time that the Hippo signaling pathway is involved in the determination of LPM cell fate by promoting venous pole identity and increases in atrial CM number ([Figure 7](#fig7){ref-type="fig"}). We show that Yap1/Wwtr1-promoted signaling increases the size of the SHF domain and that Lats1/2, by inhibiting Yap1/Wwtr1 activity, restrict it. We propose that the increased number of SHF cells in the *lats1/2* DKO embryos may result from a change in fate determination of *hand2*-negative cells, which become *hand2-*positive cells in the boundary between ALPM and PLPM. Indeed, we found that the expression of the marker of blood-cell progenitors *tal1* was repressed in the rostral region of PLPM in *lats1/2* DKO embryos. *lats1/2* mutants exhibited a subtle increase in the number of Isl1-positive atrial SHF cells, with no defect apparent in other organs. Importantly, despite the known role of Hippo signaling in CM proliferation during heart maturation, Hippo signaling was not found to affect cell proliferation during these early stages. Therefore, Hippo signaling contributes specifically to the determination of LPM differentiation.

![A schematic illustration of Hippo signaling in the ALPM and the border of the ALPM and PLPM in wildtype (WT) and Lats1/2 double knockout (DKO) embryos.\
In WT embryos, at the caudal part of the ALPM, Hippo signaling is inactive, whereas Tead-dependent transcription co-activated by Yap1/Wwtr1 is active and promotes *bmp2b* expression and *hand2* expression. Cells expressing *hand2* become the Isl1-positive SHF cells in the venous pole of the heart tube, and eventually populate the inflow tract. In the rostral region of the PLPM, Hippo signaling is active and *hand2* expression is suppressed. Cells from this region do not become cells of the venous pole. In the Lats1/2 DKO, Hippo signaling is absent in the caudal part of the ALPM, and *hand2* expression is increased. In the rostral region of the PLPM, Hippo signaling is absent and *hand2* is expressed. *hand2* expression in these cells promotes SHF specification, and these cells are integrated into the venous pole of the heart tube, and eventually populate the atrium of the heart.](elife-29106-fig7){#fig7}

We speculate that Hippo signaling cooperates with other signaling pathways to determine HF formation. For example, *hoxb5b* expression in the forelimb field limits the extent of the HF at the posterior border of the ALPM, cells of which differentiate into atrial but not ventricular CMs ([@bib50]). Furthermore, other signals generated in the pronephric field in the intermediate mesoderm and in the angiogenic field in the rostral region of PLPM are important for the regulation of cell fate at the posterior HF boundary ([@bib26]; [@bib32]).

Our results also help to clarify the origin of venous pole CMs in zebrafish and its link to the SHF. In the mouse embryo, the anterior and posterior SHF cells differentiate into the OFT/right ventricular myocardium and the IFT/atrial myocardium, respectively ([@bib15]; [@bib46]). The posterior-SHF in the HF is located caudally ([@bib1]; [@bib15]). Tead-reporter activation occurred in the caudal zone of the ALPM, and these cells were shown to become Isl1-positive, *hand2-*promoter-active CMs that are localized to the venous pole of the atrium. Both sides of the HF located caudally contributed to the venous pole of the cardiac tube. Further, mammalian SHF cells have multi-potential to differentiate into endocardial cells and smooth muscle cells in addition to myocardial cells ([@bib8]). By generating BAC transgenic fish, we found that *isl1*-promoter-active cells were detected in the atrial myocardium, endocardium, and epicardium, but not in the ventricular myocardium. Together with previous reports, our results suggest that the properties of zebrafish Isl1-positive SHF cells are similar to those of mammalian posterior-SHF cells.

Lats1/2-Yap1/Wwtr1-Tead signaling regulates Bmp2b expression, which is necessary for the formation of *hand2*-promoter-active cells in the ALPM and Isl1-expressing cells. Although previous reports have shown that *isl1*-positive and *mef2*-positive cells reside at the venous pole ([@bib12]; [@bib20]), the molecular mechanism explaining how ALPM cells give rise to these CPCs at the venous pole has remained unclear. To date, a number of signaling molecules, such as TGFβ, FGF, and BMP, have been reported to regulate arterial pole formation in the zebrafish heart tube ([@bib12]; [@bib18]; [@bib60]). We found that the Tead activation signal overlaps with the Bmp-reporter-positive signal in the ALPM. By analyzing *lats1/2* mutants and *yap1/wwtr1* mutants, we show that Hippo signaling controls *bmp2b* expression in the ALPM. Bmp-Smad inhibition expands the *tal1* expression domain to restrict LPM fate ([@bib17]). Interestingly, *hand2* expression is diminished in the *alk3* mutant, which is affected in a Bmp type I receptor 1a, at 12 ss ([@bib11]). In our experiments, Bmp-Smad inhibition results in the suppression of *hand2*-promoter-activated GFP expression at 15 hpf. Therefore, we conclude that *bmp2b* expression is positively regulated by Yap1/Wwtr1, which balances the cell fate between the HF and the blood cell field at the boundary between the ALPM and the PLPM.

We believe that the downstream targets of the Hippo-dependent Bmp-mediated signal, especially the transcription-factor-(Smads)-dependent signal, might promote distinct functions that depend on their time of action. It has been shown previously that Bmp signaling is upstream of both *hand2* and *nkx2.5* in zebrafish, and that the expression of both mRNAs is lost in Bmp signaling mutants ([@bib11]; [@bib27]; [@bib37]). However, we found here that *yap1/wwtr1* double mutants still have *hand2* expression (although this is reduced) and normal *nkx2.5* expression, even though Bmp signaling is decreased. Consistent with this possibility, Bmp signal-dependent dorso-ventral axis formation is not dependent on Lats1/2-Yap1/Wwtr1-Bmp signaling, suggesting that additional regulators of Bmp signaling are active in the ALPM. Another possibility is that Hippo signaling acts independently on both *bmp2b* expression and *hand2* expression.

In summary, we demonstrate that the Yap1/Wwtr1-Tead signal promotes Bmp2b expression and that Smad-dependent signaling subsequently defines the ALPM ([Figure 7](#fig7){ref-type="fig"}). Because Hippo signaling restricts the border between the ALPM and the PLPM, Hippo signaling may account for the restriction of SHF formation and the subsequent SHF-derived Isl1-positive IFT atrial CMs.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\      Designation                   Source or reference   Identifiers                                                                            Additional information
  or resource                                                                                                                                                             
  ---------------------------- ----------------------------- --------------------- -------------------------------------------------------------------------------------- ------------------------
  Gene (*Danio rerio*)         *yap1*                        NA                    ZDB-GENE-030131--9710                                                                  PMID:25313964

  Gene (*Danio rerio*)         *wwtr1*                       NA                    ZDB-GENE-051101--1                                                                     PMID:28350986

  Gene (*Danio rerio*)         *lats1*                       NA                    ZDB-GENE-050523--2                                                                     PMID:19842174

  Gene (*Danio rerio*)         *lats2*                       NA                    ZDB-GENE-050119--6                                                                     PMID:19842174

  Gene (*Danio rerio*)         *smad7*                       NA                    ZDB-GENE-030128--3                                                                     

  Gene (*Danio rerio*)         *bmp2b*                       NA                    ZDB-GENE-980526--474                                                                   PMID:19000838

  Gene (*Danio rerio*)         *bmp4*                        NA                    ZDB-GENE-980528--2059                                                                  

  Gene (*Danio rerio*)         *gata4*                       NA                    ZDB-GENE-980526--476                                                                   

  Gene (*Danio rerio*)         *nkx2.5*                      NA                    ZDB-GENE-980526--321                                                                   PMID:23444361

  Gene (*Danio rerio*)         *etv2*                        NA                    ZDB-GENE-050622--14                                                                    

  Gene (*Danio rerio*)         *tal1*                        NA                    ZDB-GENE-980526--501                                                                   

  Gene (*Danio rerio*)         *isl1*                        NA                    ZDB-GENE-980526--112                                                                   PMID:19395641

  Gene (*Danio rerio*)         *hoxb5b*                      NA                    ZDB-GENE-000823--6                                                                     PMID:19081079

  Strain, strain background\   AB                            ZIRC                  ZDB-GENO-960809--7;\                                                                   
  (*Danio rerio*)                                                                  RRID:[ZIRC_ZL1](https://scicrunch.org/resolver/ZIRC_ZL1)                               

  Genetic reagent\             *hand2* BAC:GFP               PMID:20627079         ZDB-ALT-110128--40;\                                                                   
  (*Danio rerio*)                                                                  RRID:[ZFIN_ZDB-ALT-110128-40](https://scicrunch.org/resolver/ZFIN_ZDB-ALT-110128-40)   

  Genetic reagent\             *hand2* BAC:tdEosFP           This paper            BacPac Resources:CH211-\                                                               
  (*Danio rerio*)                                                                  95C16 BAC                                                                              

  Genetic reagent\             *isl1* BAC:GFP                This paper            BacPac Resources:CH211-\                                                               
  (*Danio rerio*)                                                                  219F7 BAC                                                                              

  Genetic reagent\             *eef1a1l1*:galdb-hTEAD2ΔN-\   PMID:25313964         ZDB-FISH-150901--27167                                                                 
  (*Danio rerio*)              2A-mCherry                                                                                                                                 

  Genetic reagent\             *myl7*:galdb-hTEAD2ΔN-2A-\    This paper                                                                                                   
  (*Danio rerio*)              mCherry                                                                                                                                    

  Genetic reagent\             *uas*:GFP                     PMID:18202183                                                                                                
  (*Danio rerio*)                                                                                                                                                         

  Genetic reagent\             *uas*:mRFP1                   PMID:18202183                                                                                                
  (*Danio rerio*)                                                                                                                                                         

  Genetic reagent\             *myl7*:Nls-mCherry            PMID:25313964         ZDB-GENO-150218--2                                                                     
  (*Danio rerio*)                                                                                                                                                         

  Genetic reagent\             *myh6*;Nls-tdEosFP            This paper                                                                                                   
  (*Danio rerio*)                                                                                                                                                         

  Genetic reagent\             *myl7*:EGFP                   This paper                                                                                                   
  (*Danio rerio*)                                                                                                                                                         

  Genetic reagent\             *BRE*:GFP                     PMID:21337469         ZDB-ALT-110308--1;\                                                                    
  (*Danio rerio*)                                                                  RRID:[ZFIN_ZDB-ALT-110308-1](https://scicrunch.org/resolver/ZFIN_ZDB-ALT-110308-1)     

  Genetic reagent\             *tol2 transposase* mRNA       PMID:15239961                                                                                                50 pg injection
  (*Danio rerio*)                                                                                                                                                         

  Genetic reagent\             *ytip-mCherry* mRNA           PMID:25313964                                                                                                200 pg injection
  (*Danio rerio*)                                                                                                                                                         

  Genetic reagent\             *lats1*-atg MO                PMID:19842174,\       ZDB-MRPHLNO-100415--2                                                                  1.2 ng injection
  (*Danio rerio*)                                            GeneTools                                                                                                    

  Genetic reagent\             *lats2*-atg MO                PMID:19842174,\       ZDB-MRPHLNO-100415--4                                                                  1.2 ng injection
  (*Danio rerio*)                                            GeneTools                                                                                                    

  Genetic reagent\             *ajuba*-atg MO                PMID:22771034,\       ZDB-MRPHLNO-120821--5                                                                  8 ng injection
  (*Danio rerio*)                                            GeneTools                                                                                                    

  Genetic reagent\             *control* MO                  Standard control\                                                                                            5 ng injection
  (*Danio rerio*)                                            oligo, GeneTools                                                                                             

  Antibody                     Anti-GFP antibody             Abcam                 Abcam:ab13970;\                                                                        (1:300)
                                                                                   RRID:[AB_300798](https://scicrunch.org/resolver/AB_300798)                             

  Antibody                     Anti-mCherry antibody         Clontech              Clontech:632543;\                                                                      (1:300)
                                                                                   RRID:[AB_2307319](https://scicrunch.org/resolver/AB_2307319)                           

  Antibody                     Anti-Isl1 antibody            Genetex               Genetex:GTX128201                                                                      (1:100)

  Antibody                     Anti-pSmad1/5/9\              Cell Signaling\       Cell Signaling Technology:\                                                            (1:100)
                               antibody                      Technology            13820S                                                                                 

  Antibody                     Anti-chicken Alexa Fluor\     Thermo Fisher\        Thermo Fisher Scientific:\                                                             (1:300)
                               488 IgG                       Scientific            A-11039; RRID:[AB_142924](https://scicrunch.org/resolver/AB_142924)                    

  Antibody                     Anti-mouse Alexa Fluor\       Thermo Fisher\        Thermo Fisher Scientific:\                                                             (1:300)
                               546 IgG                       Scientific            A-11030; RRID:[AB_2534089](https://scicrunch.org/resolver/AB_2534089)                  

  Antibody                     Anti-rabbit Alexa Fluor\      Thermo Fisher\        Thermo Fisher Scientific:\                                                             (1:300)
                               633 IgG                       Scientific            A-21070; RRID:[AB_2535731](https://scicrunch.org/resolver/AB_2535731)                  

  Recombinant DNA\             pCR4-bluntTOPO                Thermo Fisher\        Thermo Fisher Scientific:\                                                             
  reagent                                                    Scientific            K287520                                                                                

  Recombinant DNA\             pTol2                         PMID:18202183                                                                                                
  reagent                                                                                                                                                                 

  Recombinant DNA\             pcDNA3.1                      Thermo Fisher\        Thermo Fisher Scientific:\                                                             
  reagent                                                    Scientific            V790-20                                                                                

  Recombinant DNA\             pRedET                        Gene Bridges                                                                                                 
  reagent                                                                                                                                                                 

  Recombinant DNA\             pCS2                          Clontech              RRID:[SCR_007237](https://scicrunch.org/resolver/SCR_007237)                           
  reagent                                                                                                                                                                 

  Commercial assay\            mMessage mMACHINE\            Thermo Fisher\        Thermo Fisher Scientific:\                                                             
  or kit                       kit                           Scientific            AM1340                                                                                 

  Commercial assay\            KOD FX Neo DNA\               TOYOBO                TOYOBO:KFX-201                                                                         
  or kit                       polymerase                                                                                                                                 

  Commercial assay\            Click-iT EdU Alexa 647\       Thermo Fisher\        Thermo Fisher Scientific:\                                                             
  or kit                       Imaging Kit                   Scientific            C10340                                                                                 

  Commercial assay\            DIG RNA labeling lit          Roche                 Sigma-Aldrich:11175025910                                                              
  or kit                                                                                                                                                                  

  Commercial assay\            BM-purple                     Roche                 Sigma-Aldrich:11442074001                                                              
  or kit                                                                                                                                                                  

  Commercial assay\            QuantiFast SYBR Green\        Qiagen                Qiagen:204054                                                                          
  or kit                       PCR kit                                                                                                                                    

  Chemical compound,\          DMH1                          Calbiochem            Sigma-Aldrich:203646                                                                   10 μM addition
  drug                                                                                                                                                                    

  Chemical compound,\          PTU                           Sigma-Aldrich         Sigma-Aldrich:P7629                                                                    
  drug                                                                                                                                                                    

  Software, algorithm          GraphPad Prism 7              GraphPad Software     RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)                           

  Software, algorithm          Imaris ver.8.4.1              Bitplane              RRID:[SCR_007370](https://scicrunch.org/resolver/SCR_007370)                           

  Other                        MultiNA microchip\            SHIMADZU                                                                                                     
                               electrophoresis system                                                                                                                     
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Zebrafish (*danio rerio*) strains, transgenic lines, and mutant lines {#s4-1}
---------------------------------------------------------------------

The experiments using zebrafish were approved by the institutional animal committee of National Cerebral and Cardiovascular Center (permit number: 17003) and performed according to the guidelines of the Institute. We used the AB strain as wildtype. The following zebrafish transgenic lines were used for experiments: *Tg(eef1a1l1:galdb-hTEAD2ΔN-2A-mCherry)* fish ([@bib14]), *Tg(myl7:Nls-mCherry)* fish ([@bib14]), *TgBAC*(*hand2:GFP*) fish ([@bib56]), *Tg(BRE:GFP)* fish ([@bib10]), *Tg(uas:mRFP1)* fish ([@bib4]), and *Tg(uas:GFP)* fish ([@bib4]). The *Tg(myl7:galdb-hTEAD2ΔN-2A-mCherry)* fish, *Tg(myh6:Nls-tdEosFP)* fish, *Tg (myl7:EGFP)* fish, and *TgBAC(isl1:GFP)* fish were generated as described in the experimental procedures. The knockout alleles *ncv107* for *lats1*, *ncv108* for *lats2*, and *ncv117* for *yap1* genes were generated by TALEN techniques as described in the experimental procedures. The *ncv114* allele for *wwtr1* was previously described by [@bib33].

Image acquisition and image processing {#s4-2}
--------------------------------------

To obtain the images of embryos, the pigmentation of the embryos was suppressed by the addition of 1-phenyl-2-thiourea (PTU) (Sigma-Aldrich, St. Louis, MO) into breeding E3 media. Embryos were dechorionated and mounted in 1% low-melting agarose dissolved in E3 medium. Confocal images of 2.0 μm steps were taken with a FV1200 confocal microscope system (Olympus, Tokyo, Japan) equipped with a water immersion 20x lens (XLUMPlanFL, 1.0 NA, Olympus). Images were processed with a FV10-ASW 4.2 viewer (Olympus). The distance between the *hand2*-positive region of the ALPM and the PLPM was measured using DP2-BSW software (Olympus). Cell-tracking data containing nuclei positions were analyzed using Imaris8.4.1 software (Bitplane, Zurich, Switzerland).

Generation of knockout zebrafish by TALEN {#s4-3}
-----------------------------------------

To develop knockout zebrafish, we used transcription activator-like effector nuclease (TALEN) Targeter 2.0 (<https://tale-nt.cac.cornell.edu>) to design a TALEN pair that targets *lats1*, *lats2,* and *yap1*. The target sequence of TAL-*lats1*, TAL-*lats2, and* TAL-*yap1* were 5′-TCAGCAAATGCTGCAGGAGATccgagagagcctgcgaAACCTCTCCCCGTCCTCCAA-3′, 5′-TCTCGAGGAGAGGGTGgtcgaggtggagactCAAAGGGCAAAGACCA-3′, and 5′-CCGAACCAGCACAACCctccagccggccaccagaTCGTCCATGTTCGGGG-3′, respectively (capital letters are the sequences of the left \[TAL-*lats1*-F*, lats2*-F, and *yap1*-F\] and right \[TAL-*lats1*-R, *lats2*-R, and *yap1*-R\] arms, respectively). These expression plasmids of the TALEN-pair were constructed by pT3TS-GoldyTALEN. TALEN mRNAs were synthesized in vitro using a T3 mMessage mMACHINE kit (Thermo Fisher Scientific, Waltham, MA). To induce double-strand breaks in the target sequence, 50 pg of TAL-*lats1-F* / -*lats1-R* mRNAs, TAL-*lats2-F* / -*lats2-R* mRNAs, or TAL-*yap1-F* / -*yap1-R* mRNAs were injected into one- to two-cell stage transgenic embryos. Each injected founder (F0) fish was outcrossed to wildtype fish to obtain the F~1~ progeny from individual founders. The generation of *wwtr1* knockout zebrafish has been reported previously ([@bib33]). To analyse TALEN-induced mutations, genomic DNA from F~1~ embryos was lysed by 50 μl of NaOH solution (50 mM) at 95°C for 5 min, and 5 μl of Tris-HCl (pH8.0, 1.0 M) was added on ice for 10 min. After centrifugation (13,500 rpm, 5 min), PCR reaction was performed using KOD FX Neo DNA polymerase (TOYOBO, Osaka, Japan). The genotyping PCR primers were used for amplification: *lats1* (5′-GGCACTTAACATATGCTTTTACATG-3' and 5′-TTTGCTGCTGTCTGCGGAGCTGTT-3′); *lats2* (5′-AGAGTTTGTGTGAGAGAAAACAGG-3' and 5′-GCATTGACCAGATCCTGTAGCATC-3′); *yap1* (5′-TCCTTCGCAAGGCTTGGATAATTG-3' and 5′-TTGTCTGGAGTGGGACTTTGGCTC-3′); *wwtr1* (5′-GGACGAAAAACAGGAAAAGTTC-3' and 5′-ACTGCGGCATATCCTTGTTC-3′). These amplified PCR products were analyzed using a MCE-202 MultiNA microchip electrophoresis system (SHIMADZU, Kyoto, Japan) with the DNA-500 reagent kit (SHIMADZU).

Microinjection of oligonucleotide and mRNA {#s4-4}
------------------------------------------

We injected 200 pg *ytip-mCherry* mRNA ([@bib14]), 100 or 200 pg zebrafish-*smad7* mRNA, 1.2 ng *lats1-atg* MO (5′-CCTCGGGTTTCTCGGCCCTCCTCAT-3′) ([@bib7]), 1.2 ng *lats2-atg* MO (5′-CATGAGTGAACTTGGCCTGTTTTCT-3′) ([@bib7]), 8 ng *ajuba-atg* MO (5′-TGAGTTTGATGCCAAGTCGATCCAT-3′) ([@bib52]), and 5 ng *control* MO (5′-CCTCTTACCTCAGTTACAATTTATA-3′) as previously reported ([@bib14]). These morpholinos were purchased from Gene Tools (Philomath, OR). Capped mRNAs were synthesized using the SP6 mMessage mMachine system (Thermo Fisher Scientific). Microinjection was performed using FemtoJet (Eppendorf, Hamburg, Germany). MOs, mRNA, and Tol2 plasmids were injected into blastomeres at the one- to two-cell stage.

EdU incorporation assay {#s4-5}
-----------------------

The *TgBAC(isl1:GFP);Tg(myl7:Nls-mCherry)* embryos injected with control MO or *lats1/2* MOs were incubated with 2 mM of 5-ethynyl-2-deoxyuridine (EdU) from 14 to 26 hpf or from 20 to 36 hpf, and subsequently fixed using 4% PFA at 96 hpf. EdU-incorporated cells were labelled by Click-iT EdU Alexa Fluor 647 Imaging Kits (Thermo Fisher Scientific) following the manufacturer's instructions. Images were taken using the FV1200 confocal microscope system. The number of EdU-positive *isl1*-promoter-active CMs was determined by counting the number of cells with overlapping Alexa Fluor 647-positive signal, *isl1*-promoter-activated signal and *myl7*-promoter-activated signal.

Whole-mount in situ hybridization (WISH) {#s4-6}
----------------------------------------

The antisense *hand2, isl1, bmp2b, bmp4, gata4, nkx2.5, etv2, tal1,* and *hoxb5b* RNA probes labeled with digoxigenin (DIG) were prepared using an RNA labeling kit (Roche, Basel, Switzerland). WISH was performed as previously described ([@bib14]). Colorimetric reaction was carried out using BM purple (Roche) as the substrate. To stop the reaction, embryos were washed with PBS-T, fixed with 4% PFA for 20 min at room temperature, and subsequently immersed in glycerol. Images were taken using a SZX-16 Stereo Microscope (Olympus).

Immunohistochemistry {#s4-7}
--------------------

Embryos at 14 hpf and 26 hpf were fixed by MEMFA (3.7% formaldehyde, 0.1 M MOPS, 2 mM EGTA, 1 mM MgSO~4~) for 2 hr at room temperature. After fixation, the solution was changed to 50% methanol/MEMFA for 10 min, then changed to 100% methanol at room temperature, and then stored in 100% methanol at --30°C overnight. After rehydration, embryos were washed three times for 10 min in PBBT (PBS with 2 mg/mL BSA and 0.1% TritonX-100). Embryos were blocked in PBBT with 10% goat serum for 60 min at room temperature, and subsequently incubated overnight at 4°C with primary antibodies, 1:300 diluted chicken anti-GFP antibody (ab13970, Abcam, Cambridge, UK), 1:300 diluted mouse anti-mCherry antibody (632543, Clontech, Mountain View, CA), and 1:100 diluted rabbit anti-Islet1 antibody (GTX128201, Genetex, Irvine, CA) or 1:100 diluted rabbit anti-pSmad1/5/9 antibody (13820S, Cell Signaling TECHNOLOGY, Danvers, MA) in blocking solution. Embryos were washed with PBBT five times over the course of 2 hr, with blocking solution for 60 min at room temperature, and incubated overnight at 4°C with secondary antibodies, anti-chicken Alexa Fluor 488 IgG (A-11039, Thermo Fisher Scientific), anti-mouse Alexa Fluor 546 IgG (A-11030, Thermo Fisher Scientific), and anti-rabbit Alexa Fluor 633 IgG (A-21070, Thermo Fisher Scientific) diluted 1:300 in blocking solution. Embryos were washed with PBBT five times over the course of 2 hr and stored in PBS at 4°C prior to imaging.

Quantitative real-time PCR (q-PCR) {#s4-8}
----------------------------------

Total RNAs were collected from whole-embryonic cells using TRizol (Thermo Fisher Scientific) following the manufacturer's instructions. For q-PCR, reverse transcription and RT-PCR were performed with the QuantiFast SYBR Green PCR kit (Qiagen, Hilden, Germany) in the Mastercycler Realplex (Eppendorf). The following primer set was used for amplification: *nkx2.5*-S (5′-GCTTTTACGCGAAGAACTTCC-3′), *nkx2.5*-AS (5′-GATCTTCACCTGTGTGGAGG-3′); *gata4*-S (5′-AAGGTCATCCCGGTAAGCTC-3′), *gata4*-AS (5′-TGTCACGTACACCGGAGAAG-3′); *hand2*-S (5′-TACCATGGCACCTTCGTACA-3′), *hand2*-AS (5′-CCTTTCTTCTTTGGCGTCTG-3′); *eef1a1l1*-S (5′-CTGGAGGCCAGCTCAAACAT-3′), *eef1a1l1*-AS (5′-ATCAAGAAGAGTAGTACCGCTAGCATTAC-3′) ([@bib14]).

Plasmids cDNA fragments encoding zebrafish *Hand2*, *Isl1*, *Bmp2b*, *Bmp4*, *Gata4*, *Nkx2.5*, *Etv2*, *Tal1*, *Hoxb5b* and *Smad7* were amplified by PCR using a cDNA library derived from zebrafish embryos and subcloned into a pCR4 Blunt TOPO vector (Thermo Fisher Scientific). The following primer set were used for amplification: *hand2*-S (5′-CGGGATCCCGCCATGAGTTTAGTTGGAGGGTT-3' \[containing BamHI sequence\]), *hand2*-AS (5′-GCTTTAGTCTCATTGCTTCAGTTCC-3′); *isl1*-S (5′-GCTCTAGACCTTACTTTCTTGACATGGGAGAC-3' \[containing XbaI sequence\]), *isl1*-AS (5′-GGACTGGTCGCCACCATTGGAGTA-3′); *bmp2b*-S (5′-ATGTCGACACCATGGTCGCCGTGGTCCGCGCTCTC-3' \[containing SalI sequence\]), *bmp2b*-AS (5′-TCATCGGCACCCACAGCCCTCCACC-3′); *bmp4*-S (5′-CGGGATCCCATGATTCCTGGTAATCGAATGC-3' \[containing BamHI sequence\]), *bmp4*-AS (5′-CATTTGTACAACCTCCACAGCAAG-3′); *gata4*-S (5′-GTGAATTCATGTATCAAGGTGTAACGATGGCC-3' \[containing EcoRI sequence\]), *gata4*-AS (5′-GAGCTTCATGTAGAGTCCACATGC-3′); *nkx2.5*-S (5′-GCTCTAGATTCCATGGCAATGTTCTCTAGCCAA-3' \[containing XbaI sequence\]), *nkx2.5*-AS (5′-GATGAATGCTGTCGGTAAATGTAG-3′); *etv2*-S (5′-GTGAATTCCTGGATTTTACACAGAAGACTTCAGA-3' \[containing EcoRI sequence\]), *etv2*-AS (5′-CCACGACTGAGCTTCTCATAGTTC-3′); *tal1*-S (5′-GTGAATTCGAAATCCGAGCAATTTCCGCTGAG-3' \[containing EcoRI sequence\]), *tal1*-AS (5′-CTTAGCATCTCCTGAAGGAGGTCGT-3′); *hoxb5b*-S (5′-GTGAATTCCCAAATGAGCTCTTATTTTCTAAACTCG-3' \[containing EcoRI sequence\]), *hoxb5b*-AS (5′-GATGTGATTTGATCAATTTTGAAACGCGC-3′); *smad7*-S (5′-AGGGATCCTCCCGCATGTTCAGGACCAAACGAT-3' \[containing BamHI sequence\]), *smad7*-AS (5′-GAAGGCCTTTATCGGTTATTAAATATGACCTCTAACC-3' \[containing StuI sequence\]). The cDNA of zYtip was previously amplified and cloned into the pCS2 vector (Clontech) ([@bib14]). The DNA encoding Smad7 was subcloned into the pCS2 vector to construct the pCS2-smad7. All of the cDNAs amplified by PCR using cDNA libraries were sequenced. Mutations were also confirmed by sequencing.

Generation of transgenic lines {#s4-9}
------------------------------

To monitor atrial CM development, we established a transgenic (Tg) zebrafish line expressing a nuclear localization signal (Nls)-tagged tandem Eos fluorescent protein under the control of the *myosin heavy chain 6* (*myh6*) promoter; *Tg*(*myh6:Nls-tdEosFP*). pTol2-*myh6* vector was constructed by modifying the pTol2 vector and inserting the *myh6* promoter as a driver of the expression of the target molecule. The primers used to amplify the *myh6* promoter were 5′-AGAGCTAAAGTGGCAGTGTGCCGAT-3' and 5′-TCCCGAACTCTGCCATTAAAGCATCAC-3′. An oligonucleotide encoding Nls derived from SV40 (PKKKRKV) was inserted into pcDNA-tdEosFP (MoBiTec, Göttingen, Germany) to generate the plasmids expressing Nls-tagged tandem Eos fluorescent protein (Nls-tdEosFP). The Nls-tdEosFP cDNA was subcloned into the pTol2-*myh6* vector to construct the pTol2-*myh6*:Nls-tdEosFP plasmids.

To monitor CM-specific Yap1/Wwtr1-dependent transcriptional activation, we developed a transgenic fish that expresses human (h) TEAD2 lacking the amino-terminus (1--113 aa) and fused with the Gal4 DNA-binding domain followed by 2A mCherry under the control of the *myosin light polypeptide 7* (*myl7*) promoter; *Tg(myl7:galdb-hTEAD2ΔN-2A-mCherry).* This Tg fish was crossed with *Tg(uas:GFP)* reporter fish to obtain *Tg(myl7:galdb-hTEAD2ΔN-2A-mCherry);Tg(uas:GFP)*. The pTol2-*myl7* vector and the pcDNA3.1 vector containing human *TEAD2ΔN* cDNA fused to the DNA-binding domain of Gal4 (pcDNA3.1-galdb-hTEAD2ΔN) were constructed as previously described ([@bib14]). The Gal4db-hTEAD2ΔN cDNA was subcloned into the pTol2-*myl7* vector to construct the pTol2-*myl7*:galdb-hTEAD2ΔN plasmids.

To monitor CM development, we developed a transgenic line that expresses EGFP under the control of the *myl7* promoter; *Tg(myl7:EGFP)*. The EGFP was subcloned into a pTol2-*myl7* vector to construct the pTol2-*myl7*:EGFP plasmids. All of the cDNAs amplified by PCR using cDNA libraries were confirmed by DNA sequencing.

To monitor SHF development, we established a transgenic line that expressed GFP under the control of *isl1* BAC promoter/enhancer; the *TgBAC(isl1:GFP).* pRedET plasmid (Gene Bridges, Heidelberg, Germany) was introduced into *E. coli* containing a CH211-219F7 BAC clone encoding the *isl1* gene (BacPAC resources) by electroporation (1800V, 25 mF, 200 Ω) to increase the efficiency of homologous recombination, as previously described ([@bib3]). Tol2 long terminal repeats in opposite directions flanking an ampicillin resistance cassette were amplified by PCR using Tol2_amp as a template, and these sequences were inserted into the BAC vector backbone. The cDNA encoding both GFP and a kanamycin resistance cassette (GFP_KanR) was amplified by PCR using a pCS2-GFP_KanR plasmid as a template, and inserted into the start ATG of the *isl1* gene. Primers to amplify the GFP_KanR for *isl1* gene were 5′-gggccttctgtccggttttaaaagtggacctaacaccgccttactttcttACCATGGTGAGCAAGGGCGAGGAG-3' and 5′-aaataaacaataaagcttaacttacttttcggtggatcccccatgtctccTCAGAAGAACTCGTCAAGAAGGCG-3' (small letters are the homology arm to the BAC vector, whereas capital letters are the primer binding site to the template plasmid).

Tol2-mediated zebrafish transgenesis was performed by injecting 30 pg of the transgene plasmid together with 50 pg *tol2 transposase* mRNA, followed by subsequent screening of F~1~ founders and establishment of single-insertion transgenic strains through selection in F~3~ generations.

Photoconversion {#s4-10}
---------------

We performed photoconversion experiments by examining the transient *hand2-promoter*-dependent expression of tdEosFP. *Tg(myl7:EGFP)* embryos were injected with 30 pg of pTol2-*hand2* BAC:tdEosFP plasmid along with 50 pg *tol2 transposase* mRNA. To trace ALPM cells, the caudal region of the left or right ALPM was photoconverted by a 405 nm laser at 15 hpf (12 ss). The photoconverted cells expressing red fluorescence were traced in the heart region at 52 hpf.

To construct the pTol2-*hand2* BAC:tdEosFP, pRedET plasmid was introduced into *E. coli* containing a CH211-95C16 BAC clone encoding the *hand2* gene (BacPAC resources) by electroporation. Tol2 long terminal repeats in opposite directions flanking an ampicillin resistance cassette were amplified by PCR using Tol2_amp as a template, and were inserted into the BAC vector backbone. The cDNA encoding tdEosFP together with a kanamycin resistance cassette (tdEosFP_KanR) was amplified by PCR using the pCS2-tdEosFP_KanR plasmid as a template, and then inserted into the start ATG of the *hand2* gene. Primers to amplify the tdEosFP_KanR for the *hand2* gene were 5′-ccaaagcgtactccgtctgtggttcgccgtagggtatagacaagtctgtcACCATGAAGATCAACCTCCGTATGGAAG-3' and 5′-tagccgtcatggtgcatcacagggtggtggggaaaccctccaactaaactTCAGAAGAACTCGTCAAGAAGGCG-3' (small letters represent the homology arm to BAC vector, and capital letters the primer binding site to the template plasmid).

Chemical treatment {#s4-11}
------------------

The *TgBAC(hand2:GFP);Tg(myl7:Nls-mCherry)* embryos and the T*gBAC(isl1:GFP);Tg(myl7:Nls-mCherry)* embryos were treated with 10 μM DMH1 (203646, Sigma-Aldrich), an inhibitor of Bmp signaling, from 14 hpf to 26 hpf. As a control, embryos were incubated in E3 solution containing DMSO. These embryos were imaged at 26 hpf.

Data analysis and statistics {#s4-12}
----------------------------

Data were analyzed using GraphPad Prism 7 (GraphPad Software, La Jolla, CA). All columns shown in histograms represent a mean ± SEM. The statistical significance of multiple groups was determined by one-way ANOVA with Bonferroni's *post hoc* test. The numbers of atrial and ventricular CMs at 74 hpf were analyzed by Student's t-test. The statistical significance of two groups was determined by Student's t-test.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Hippo signaling restricts cells in the second heart field that differentiate into Islet-1-positive atrial cardiomyocytes\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Didier Stainier as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In this manuscript, Fukui et al. examine the role of the Hippo signaling pathway in regulating development of the inflow tract (IFT) in the zebrafish heart. Using a series of elegant experiments and detailed quantification, the authors demonstrate that Hippo signaling is active in the developing IFT and that enhanced Hippo signaling results in an increased number of IFT cells, as labelled by hand2 and islet1 expression, as well as increased atrial cell number at later stages. The mechanism for the increase in cell number is not through proliferation but rather through increased differentiation of cardiomyocytes. Furthermore, the authors demonstrate that Bmp signaling is increased in the context of enhanced Hippo signaling, and they propose to place Bmp signaling downstream of Hippo and upstream of hand2 and islet1. Previous work has shown that Hippo signaling in mouse embryos determines heart size by regulating cardiomyocyte proliferation. In contrast, this work suggests that Hippo can also affect heart size by regulating specification of IFT cells. Thus, this study is significant on several levels: it expands our understanding of the roles of the Hippo signaling pathway in regulating heart size, it adds to our understanding of the pathways that regulate the formation of the IFT, and it has the potential to provide broader insights into the mechanisms that control of cardiac differentiation and patterning. However, certain elements of the authors\' conclusions are not fully supported by the data presented here. Several issues require further investigation and/or clarification in order to make a clear case for their model.

Essential revisions:

1\) Importantly, the authors need to provide further evidence to support their conclusions regarding the differential fates of the left and right caudal ALPM. Previous cell tracking work has shown that cells from the left LPM form the dorsal side of the cardiac tube while cells from the right LPM form the ventral side of the cardiac tube (PMID: 18267096). Different from the description in the current manuscript, the older work showed that both the right and left LPM cells contributed to the venous pole. However, the dorsal side of the tube extends more anteriorly compared to the ventral side. Looking closely at the data provided by the authors (e.g. by playing the last 3 hours (equivalent of 2 secs) of their movie backward and forward rapidly), one gets the impression that the right caudal ALPM also contributes to the venous pole at the ventral side. Likely due to the tissue depth at the ventral surface, the fluorescence intensity of these cells is weaker and, therefore, difficult to track. To definitively state that the left and right sides contribute to the venous and arterial poles, respectively, the authors should provide higher resolution (and 3D) tracking of both the right and left ALPM cells. In addition, complementary lineage tracing experiments (using photoconversion or other cell labeling techniques) should be employed to follow the cells labeled in the right and left ALPM to their destination in the heart at 48 hpf.

2\) The authors highlight the expression of the Tead reporter in the left caudal ALPM, but it is not clear whether or not this reporter is expressed in the right caudal ALPM. This needs to be clarified.

3\) The ectopic hand2 expression and bmp2 expression in lats1/2 mutants is bilateral and not restricted to the left ALPM (Figures 5 and 6). How does this reconcile with the authors\' suggested laterality of Hippo signaling (as shown in their model in Figure 7)?

4\) In Figure 6, the authors show enhanced expression of bmp2b in lats1/2 mutants and loss of bmp2 expression in yap/wwtr mutants. The effects are visible in the entire ALPM and head region, while their data shown in Figure 3 suggests that Yap1 is only active in the posterior ALPM. This discrepancy is not addressed. How do the authors fit these data with their model in which Hippo signaling activity is different in the posterior versus anterior ALPM?

5\) It\'s possible that an increase in signaling through either pathway (Hippo or Bmp) would result in increased cells at the IFT. Is there increased TEAD reporter activity following bmp2b heat-shock?

6\) To reduce BMP signaling, the authors inject mRNA for smad7 (inhibitory Smad). It is not clear why the authors try to block BMP signalling during early stages of development since BMP signaling is required for proper dorsal-ventral patterning. Did the authors observe DV patterning defects in these experiments?

7\) The authors imply that lats1 and lats2 have a special influence on the Isl1-positive atrial cells and do not affect the numbers of the Isl1-negative atrial cells. However, this is not clearly demonstrated by the data presented here: the total number of atrial cells is presented at one stage, and the number of Isl1-positive cells is presented at a substantially earlier stage. Does the change in the number of Isl1-positive cells account for the entirety of the difference in atrial size? Similarly, is the impact of overexpressing bmp2b and/or adding DMH1 specific to the Isl1-positive population, or do these manipulations affect the entire atrium?

8\) The role of Yap1/Wwtr1 in promoting hand2 expression needs further clarification. The authors point to the reduction of hand2 expression in yap1;wwtr1 mutants, but it is unclear how specifically this phenotype relates to the regulation of hand2. Is the entire ALPM reduced in yap1;wwtr1 mutants? In addition, the relationship between the cardia bifida phenotype and the reduced hand2 expression in the yap;wwtr1 mutant should be more clearly articulated. The yap;wwtr1 mutant appears smaller than the control embryo shown. Corresponding bright field images would be helpful here.

\[Editors\' note: further revisions were requested prior to acceptance, as described below. The authors' plan for revisions was approved and the authors made a formal revised submission.\]

Thank you for sending your revised article entitled \"The Hippo signaling suppresses the differentiation of cardiac precursor cells from lateral plate mesoderm prior to establishment of the heart field in zebrafish\" for peer review at *eLife*. Your revised article has been evaluated by its original three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation is being overseen by Didier Stainier as the Senior Editor.

The reviewers have discussed their reviews with one another, and their discussion has highlighted some remaining issues (elaborated below) that still need to be addressed. Since some of these revisions would likely require you to perform new experiments, we ask that you respond to this letter within the next two to three weeks with a specific action plan and timetable for the completion of the additional work. The Reviewing Editor and reviewers will then consider your plans, assess the feasibility of an effective response to their concerns, and offer a binding recommendation (such as an official invitation to submit a second revision of your manuscript to *eLife*). Alternatively, if you would prefer to submit your manuscript elsewhere, rather than revising it again for *eLife*, please let us know.

In this revised manuscript, the authors have made multiple amendments to their original submission, including new data and new interpretations, and many of these have helped to clarify issues from the original manuscript that needed to be addressed. However, several concerns remain that require further attention. Importantly, while the current version of the manuscript certainly demonstrates an influence of lats1 and lats2 on the development of the venous pole, it stops short of clearly articulating a mechanistic connection between the Hippo pathway and the differentiation of venous pole cells. Specifically, some of the data shown appear to be inconsistent with or to contradict the authors\' model, as described below.

Essential revisions:

1\) From the authors\' data, it is clear that there is a positive relationship between Bmp signaling and the formation of venous pole cells. It is also clear that Hippo signaling has a negative influence on bmp2b expression. However, it is not yet clear whether the caudal boundary of hand2 expression in the ALPM is set by Hippo signaling repressing bmp2b expression at that location. While it may be challenging to test a model that relates Hippo signaling to bmp2b expression directly, it would be beneficial for the authors to clarify aspects of their story that are not consistent with that model. For example, while bmp2b expression is increased in lats1;2 mutants, it does not appear to be expanded, and this seems to contradict the authors\' model. Can the authors clarify this, or adjust their model accordingly?

2\) The authors conclude that Yap1 activity in the ALPM induces Bmp signaling and that Bmp signaling activates hand2 and Isl1 expression, but this conclusion is too simple. Published data in zebrafish have shown that Bmp signaling is upstream of both hand2 and nkx2.5. (Both are lost in Bmp signaling mutants.) Yap1/wwtr1 double mutants still have hand2 expression (although reduced) and normal nkx2.5 expression. The authors do not address whether Bmp signaling is affected in the Yap1/wwtr1 mutants using the bre:gfp reporter line (they only show that bmp2b expression is reduced in the ALPM). Neither do they try to rescue the Yap1/wwtr1 phenotype with Bmp overexpression. The proposed model suggesting that Yap1 signaling is upstream of Bmp signaling is therefore an oversimplification and needs adjustment.

3\) The phenotype shown for an embryo overexpressing smad7 mRNA does not seem to be a standard BMP-induced dorsalization phenotype, which is surprising. The appearance of the embryo in Figure 6---figure supplement 3A and the fragmented cells in Figure 6H suggest that the overexpression of smad7 may be causing cell death. Additionally, the cardiac phenotype attained after smad7 overexpression was not quantified, weakening the conclusions made from this experiment. If the authors intend to demonstrate cell-autonomous epistasis, they will likely need to use another approach. (Perhaps overexpression of a dominant-negative Bmp receptor?)

4\) In the experiment using DNA injection to induce mosaic Bmp2b expression (Figure 6---figure supplement 2A), the cells expressing bmp2b-2A-mCherry look fragmented, suggesting toxicity. The tissue on the left side also looks necrotic and the Yap1 reporter is very weak, while the authors state that it is unaffected. These results are not appropriate for inclusion in the manuscript. It is unclear why the authors did not use the available hsp70:bmp2b transgenic line to generate mosaic embryos through transplantation.

5\) In their revised manuscript, the authors conclude that venous pole cells originate on both sides of the ALPM, but they also state that \"more cells moved from the left ALPM to the venous pole compared to the cells coming from the right ALPM\". It is not clear that this semi-quantitative comparison is warranted, since it does not seem as if the authors tracked all of the cells on both sides of the ALPM. In Video 1, the authors compare five cells on the left to two cells on the right and state that this is representative of six independent experiments. How do the numbers compare among the six experiments? Is this a quantitatively reproducible observation? Do the photoconversion experiments (Figure 3D) reinforce the view that more venous pole cells come from the left than from the right? It is challenging to make a quantitative conclusion from this type of mosaic analysis. The authors should clarify the basis for this quantitative comparison between the left and right sides, or, alternatively, adjust their interpretation. Additionally, it would be helpful if the authors could clarify what criteria they used to define whether or not a tracked cell (or a photoconverted cell) became part of the venous pole in these experiments. Do the seven tracked cells in Video 1 account for the entirety of the venous pole?

6\) The authors have revised their title and Abstract to accompany the changes to their model that they have incorporated into their revised manuscript. It may be beneficial to consider revising these further in order to better emphasize the key points that are most strongly supported by the current text. For example, the title claims that Hippo signaling \"suppresses the differentiation of cardiac precursor cells\" but it is not clear that suppression of differentiation is shown here. More venous pole cells are produced when Hippo signaling is inhibited, but it is not evident whether this occurs through alteration of differentiation (as opposed to alteration of specification or proliferation). To make this claim, the authors would need to provide additional data in support of this conclusion. Also, the authors emphasize that the activity of Hippo signaling occurs \"prior to establishment of the heart field\", but it is not clear what they mean by this phrase. When do they consider the heart field to be established, and what is the significance of its establishment as it relates to the conclusions of their manuscript? Overall, it would be more effective if the title and Abstract emphasized formation of the venous pole specifically, as that seems to be the focus of the manuscript.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Hippo signaling determines the number of atrial cells that originate from the anterior lateral plate mesoderm in zebrafish\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Didier Stainier (Senior editor), and three reviewers, one of whom is a member of our Board of Reviewing Editors.

The manuscript has been improved through its second round of revision, both by adding new data and by removing less convincing elements. Altogether, the revisions have streamlined and strengthened the overall clarity of the message regarding the impact of the Hippo signaling pathway on the number of venous pole cells in zebrafish, while toning down some of the more speculative or inconsistent aspects. However, there are some remaining issues that need to be addressed, as outlined below:

1\) With each revision of this manuscript, the authors have modified their title and Abstract to accompany the changes in their message. Further modification would help the current title to fit more closely with the main point of the paper, which revolves around the pathways regulating the number of venous pole (Isl1+) cells. The new title and Abstract seem to emphasize the whole atrium, even though the take-home message of the data is focused on the venous pole. Further adjustment is needed to align the title and Abstract with the rest of the manuscript.

2\) The data that are provided to argue that overexpression of smad7 (as in Figure 6) is non-toxic are not convincing. The authors have undertaken control experiments, examining whether embryos injected with smad7 mRNA look healthy, but this context is quite different from the mosaic scenario presented in the experiments, in which three different mRNAs are co-injected. It remains unexplored whether this cocktail is causing cell death (and therefore loss of hand2 expression) and therefore no conclusion can be drawn from this experiment. Therefore, the experiments utilizing smad7 overexpression should be removed from the manuscript.

3\) It appears premature for the authors to conclude a direct, linear relationship connecting Hippo signaling, Bmp signaling, and Hand2 expression. Without a formal epistasis experiment (e.g. DMH1 treatment in lats1/2 LOF and measuring the hand2 response), it does not seem appropriate to suggest this hierarchy. The most appropriate representation would be to conclude that Hippo signaling acts on both Bmp signaling and Hand2 expression. These could be independent influences, or they could be linked, but the data do not clearly support the direct linkage.

4\) The authors should look through the manuscript carefully, as there are a number of errors in the text. Some examples, spotted by reviewers, are listed here:

\- Instances where \"specification\" is used, when differentiation is appropriate

\- \"compared to humans\" would read better as \"compared to mouse and humans\", given it follows a description of mice

\- \"transcriptional factor\" should read \"transcription factor\"

\- \"restricts determines\" is tautological and needs altering

\- \"frameshifts\" should read \"frameshift mutations\"

\- \"faithfully recapitulates isl1 expression in vivo\" is an overstatement if all isl1 expression was not assessed.

\- "Interestingly, the gap length of WT embryos was significantly shorter than that of the lats1wt/ncv107lats2ncv108 embryos, the lats1/2 DKO embryos and the lats1/2 morphants." However, the data in Figure 5 shows that gap length in wt embryos is larger.

5\) It would be beneficial for the authors to review their choices of cited articles. In some cases, it seems as if the citations may not be the best choices to fully support the statements made. For example, does Hami et al. (2011) strongly support the points for which it is cited in the Introduction (that SHF cells come from the lateral and caudal ALPM, and that Isl1+ cells give rise to the inflow tract)?

10.7554/eLife.29106.032

Author response

> Essential revisions:
>
> 1\) Importantly, the authors need to provide further evidence to support their conclusions regarding the differential fates of the left and right caudal ALPM. Previous cell tracking work has shown that cells from the left LPM form the dorsal side of the cardiac tube while cells from the right LPM form the ventral side of the cardiac tube (PMID: 18267096). Different from the description in the current manuscript, the older work showed that both the right and left LPM cells contributed to the venous pole. However, the dorsal side of the tube extends more anteriorly compared to the ventral side. Looking closely at the data provided by the authors (e.g. by playing the last 3 hours (equivalent of 2 secs) of their movie backward and forward rapidly), one gets the impression that the right caudal ALPM also contributes to the venous pole at the ventral side. Likely due to the tissue depth at the ventral surface, the fluorescence intensity of these cells is weaker and, therefore, difficult to track. To definitively state that the left and right sides contribute to the venous and arterial poles, respectively, the authors should provide higher resolution (and 3D) tracking of both the right and left ALPM cells. In addition, complementary lineage tracing experiments (using photoconversion or other cell labeling techniques) should be employed to follow the cells labeled in the right and left ALPM to their destination in the heart at 48 hpf.

As the reviewers critically commented, the contribution of both sides of the cells in the ALPM to venous pole should be carefully examined. We have performed additional cell tracking experiments that show that the cells in the caudal regions of both sides of ALPM move to the venous pole (New Figure 3A, 3B, and Video 1). The number of the cells from the left ALPM was greater than those from the right ALPM. The cells in the both sides of LPM move toward the cardiac disk. Those cells stay in the arterial pole. Therefore, the cells in the both sides of ALPM can become both venous and arterial pole cells. In the revised manuscript, we decline our previous conclusion that the cells in the left and right ALPM become venous and arterial pole cells, respectively. Instead, we state that both sides of ALPM cells become the cells in the venous pole. Initially, we tried to understand the origin of the IFT of the atrium. Therefore, we still focus on the venous pole cells that give rise to the IFT cells.

In addition, following the reviewer's advice, we have performed the photoconversion experiments using the embryos transiently injected with *hand2BAC*:tdEosFP and photoconverted at 12 ss. We have confirmed that both the left and right ALPM cells are localized in the inflow tract (IFT) of the atrium at 52 hpf (New Figure 3D). Therefore, we have concluded that the cells in the caudal region of the left ALPM cells contribute to venous pole and inflow tract development more than those in the right ALPM. These results are consistent with the previous report, although it is worth mentioning that more cells in the left ALPM move to the venous pole than those in the right ALPM.

> 2\) The authors highlight the expression of the Tead reporter in the left caudal ALPM, but it is not clear whether or not this reporter is expressed in the right caudal ALPM. This needs to be clarified.

We admit that we should clarify the expression of Tead reporter in the both sides of ALPM. To examine whether the expression of Tead reporter is observed in the right side of the caudal region of the ALPM, we crossed *TgBAC(hand2:GFP)* with *Tg(eef1a1l1:galdb-hTEAD2ΔN-2A-mCherry);Tg(uas:mRFP1)*. We found that Tead reporter is expressed in both the left and right sides of entire ALPM (New Figure 3E). Collectively, our new data demonstrate that Hippo signaling functions in the entire ALPM. Therefore, this data suggests -- together with the results showing the *hand2* promoter-activated cells -- that Hippo signaling in the ALPM contribute to the *hand2*-positive cell formation in the ALPM.

> 3\) The ectopic hand2 expression and bmp2 expression in lats1/2 mutants is bilateral and not restricted to the left ALPM (Figures 5 and 6). How does this reconcile with the authors\' suggested laterality of Hippo signaling (as shown in their model in Figure 7)?

As the reviewers were concerned, given that the results of new experiments suggest that Hippo signaling functions in bilaterally, we have declined our previous conclusion and propose that hippo signaling functions in both the left and the right ALPM (New revised Figure 7) in the revised manuscript. This conclusion is consistent with our previous data showing the bilateral expression of both *hand2* and *bmp2b* in the ALPM as the reviewers pointed out in the *lats1/2* mutants.

> 4\) In Figure 6, the authors show enhanced expression of bmp2b in lats1/2 mutants and loss of bmp2 expression in yap/wwtr mutants. The effects are visible in the entire ALPM and head region, while their data shown in Figure 3 suggests that Yap1 is only active in the posterior ALPM. This discrepancy is not addressed. How do the authors fit these data with their model in which Hippo signaling activity is different in the posterior versus anterior ALPM?

In the previous experiments, we just focused on the caudal region of the ALPM using the certain layer cells as the reviewers pointed out. We admit that we should carefully track the entire ALPM cells and the expression of Tead reporter as in the reply to the comments (1) and (2). In new Figure 3E and new Figure 3---figure supplement 1A, Tead expression is found in the entire ALPM but not in the rostral PLPM. Therefore, these results are consistent with the results of the enhanced expression of *bmp2b* in *lats1/2* mutant and loss of *bmp2b* expression in *yap1/wwtr1* mutants at the same developmental stage (Figure 6B), suggesting that Hippo signaling restricts the expression of *bmp2b* in the ALPM. These results were included in the model of new Figure 7.

> 5\) It\'s possible that an increase in signaling through either pathway (Hippo or Bmp) would result in increased cells at the IFT. Is there increased TEAD reporter activity following bmp2b heat-shock?

Exactly, the number of the cells at the venous pole correlates with that of the IFT. Indeed, the results shown in Figure 1 prompted us to examine the cell number at the venous pole that is determined by Hippo signaling. We have demonstrated that both Tead and Bmp reporters are activated at the venous pole at 24 hpf (Figure 1---figure supplement 2B, and Figure 6E).

According to the reviewers' suggestion, we have over-expressed *bmp2b* by the injection of *hsp70l:bmp2b-2A-mCherry* in the Tead reporter embryos. In line with the previous results, *bmp2b* expression did not affect Tead reporter activity (New Figure 6---figure supplement 2A). This new data supports our model that Hippo signaling functions upstream of Bmp-Smad signaling.

> 6\) To reduce BMP signaling, the authors inject mRNA for smad7 (inhibitory Smad). It is not clear why the authors try to block BMP signalling during early stages of development since BMP signaling is required for proper dorsal-ventral patterning. Did the authors observe DV patterning defects in these experiments?

We admit that we did not have any better method to spatio-temporally block BMP signaling in the ALPM. Therefore, *smad7* mRNA injection was the only possible way for us to inhibit BMP signaling (Figure 6G and H). We have examined the phenotype of general inhibition of Bmp signaling, dorsalized development. As shown in the New Figure 6---figure supplement 3A and 3B, injection of *smad7* mRNA dose-dependently increased dorsalization of the embryos. Therefore, we conclude that *smad7* mRNA can block Bmp-Smad signaling to examine the Bmp-dependent signal for *hand2* expression.

> 7\) The authors imply that lats1 and lats2 have a special influence on the Isl1-positive atrial cells and do not affect the numbers of the Isl1-negative atrial cells. However, this is not clearly demonstrated by the data presented here: the total number of atrial cells is presented at one stage, and the number of Isl1-positive cells is presented at a substantially earlier stage. Does the change in the number of Isl1-positive cells account for the entirety of the difference in atrial size? Similarly, is the impact of overexpressing bmp2b and/or adding DMH1 specific to the Isl1-positive population, or do these manipulations affect the entire atrium?

Unfortunately we cannot prove the direct relevance of the number of *isl1*-posoitve cells in the earlier stage to that of atrial cardiomyocytes in the later stage, because we have neither Tg line nor imaging system that allow us to 3-dimesionally track the cell fate from 20 hpf to 3 dpf. To show the direct contribution of Isl1-positive SHF cells to the formation of atrial cardiomyocytes, we further need to cell track of *isl1* promoter*-*activated cells. In our data, the actual increase of the atrial CM was about 20 cells in the *lats1/2* mutants at 74 hpf (Figure 1B). This increase paralleled the increase in the *isl1* promoter-activated cells at 26 hpf (Figure 4E). In addition, the number of *isl1* promoter-activated cell at 26 hpf and 96 hpf was about 25 cells (Figure 4C and 4E), suggesting that *isl1*-positive cells does not increase during this period, although we cannot exclude the possibility that *isl1* promoter-activated cells become negative, while *isl1*-negative cells could become positive. At least, these data imply that Hippo signaling determines the number of *isl1*-positive cells that give rise to atrial cardiomyocytes.

We thank the reviewers for suggesting an experiment that supports our conclusions. According to the reviewers' advice, we examined the effect of inhibition of Bmp signaling on *isl1*-positive SHF cells and *isl1*-negative cardiomyocytes. Inhibition of Bmp signaling resulted in a decrease in the number of *isl1*-positive cells but not in that of *myl7*-positive cardiomyocytes (New Figure 6I and 6J). Therefore, we assume that the increased number of atrial cardiomyocytes in the *lats1/2* mutants is ascribed to the increased number of *isl1*-positive cells

> 8\) The role of Yap1/Wwtr1 in promoting hand2 expression needs further clarification. The authors point to the reduction of hand2 expression in yap1;wwtr1 mutants, but it is unclear how specifically this phenotype relates to the regulation of hand2. Is the entire ALPM reduced in yap1;wwtr1 mutants? In addition, the relationship between the cardia bifida phenotype and the reduced hand2 expression in the yap;wwtr1 mutant should be more clearly articulated. The yap;wwtr1 mutant appears smaller than the control embryo shown. Corresponding bright field images would be helpful here.

Following the reviewers' suggestion, we looked at the entire ALPM by simultaneous monitoring bright field images and confirmed that *hand2* expression is significantly reduced in the entire anterior region (New Figure 2---figure supplement 2C). In the paper by the group of Prof. Yelon (Development, 2000), *hand2* mutants (*han*) show a reduction of *hand2* expression and exhibit cardia bifida, suggesting that the reduced *hand2*-dependent signaling leads to cardia bifida. The *yap1/wwtr1* mutants showed reduced *hand2* expression and cardia bifida (Figure 5D, new Figure 2---figure supplement 2C and 2D). We further found that the expression of *nkx2.5*, one of ALPM-derived FHF marker, was not affected in *yap1/wwtr1* mutants (New Figure 2---figure supplement 2D). This data indicates that Hippo signaling is not involved in the differentiation of FHF-derived cardiomyocyte but inhibits Yap1/Wwtr1-dependent *hand2* expression in the ALPM.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> Essential revisions:
>
> 1\) From the authors\' data, it is clear that there is a positive relationship between Bmp signaling and the formation of venous pole cells. It is also clear that Hippo signaling has a negative influence on bmp2b expression. However, it is not yet clear whether the caudal boundary of hand2 expression in the ALPM is set by Hippo signaling repressing bmp2b expression at that location. While it may be challenging to test a model that relates Hippo signaling to bmp2b expression directly, it would be beneficial for the authors to clarify aspects of their story that are not consistent with that model. For example, while bmp2b expression is increased in lats1;2 mutants, it does not appear to be expanded, and this seems to contradict the authors\' model. Can the authors clarify this, or adjust their model accordingly?

We agree with the reviewer that this needs clarification. *bmp2b* expression is actually very difficult to quantify and we did not obtain conclusive results when measuring its expression domain. Due to the presence of the eye near the *bmp2b* expression domain and the necessity of dissecting the yolk, the measure of the expression domain highly variable from embryo to embryo. However, we found that *bmp2b* expression levels in the *lats1/2* mutants examined by *in situ* hybridization at 10 somite-stage (ss) were greater than that of the control (Figure 6B). We further show that *bmp2b* expression was increased two-fold in *lats1/2* morphants compared to controls via qPCR performed at 24 hpf (see [Author response image 1](#respfig1){ref-type="fig"}).

Bmp2b being a secreted protein, we hypothesize that increased Bmp2b expression levels might lead to an expanded BMP signaling domain as a result of an increased protein accumulation, thus leading to the activation of *hand2* expression more caudally in the ALPM. Since this hypothesis remains speculative at this point, we eliminated the previous statement "*bmp2b* expression is induced by Lats1/2-Yap1/Wwtr1 signaling in the rostral region of PLPM" in the revised manuscript.

![Quantitative-PCR analyses of expression of bmp2b mRNAs in the whole embryos at 24 hpf injected with the lats1/2 MOs (n=4).\
Relative expression of mRNA in the morphants to that of the control is calculated.](elife-29106-resp-fig1){#respfig1}

We changed the model accordingly by deleting the description of cell autonomous signaling because we cannot exclude the possibility that BMP secreted from the ALPM cells might affect BMP signaling in a non-cell autonomous manner.

> 2\) The authors conclude that Yap1 activity in the ALPM induces Bmp signaling and that Bmp signaling activates hand2 and Isl1 expression, but this conclusion is too simple. Published data in zebrafish have shown that Bmp signaling is upstream of both hand2 and nkx2.5. (Both are lost in Bmp signaling mutants.) Yap1/wwtr1 double mutants still have hand2 expression (although reduced) and normal nkx2.5 expression. The authors do not address whether Bmp signaling is affected in the Yap1/wwtr1 mutants using the bre:gfp reporter line (they only show that bmp2b expression is reduced in the ALPM). Neither do they try to rescue the Yap1/wwtr1 phenotype with Bmp overexpression. The proposed model suggesting that Yap1 signaling is upstream of Bmp signaling is therefore an oversimplification and needs adjustment.

The reviewers are right; this point deserves clarification. A possible explanation for the discrepancy of Bmp2b-dependent transcription of both *hand2* and *nkx2.5* between the previous reports and our results is that Yap1/Wwtr1-Bmp2b downstream signal varies spatially and temporally to regulate heart formation. We believe that the downstream targets of Bmp-mediated signal, especially the transcription factors (Smads)-dependent signal, promote distinct targets depending on their time of action. In support of this possibility, the Tead reporter's activation is observed in the whole ALPM at 10 ss (New Figure 4E), whereas it was only active in the cells of the venous pole at 24 hpf (Figure 1---figure supplement 2B).

In order to address this critical point further, we performed additional experiments to define more precisely whether Yap1/Wwtr1 signaling is upstream of Bmp signaling. We followed the editor's suggestion and studied the *Tg(BRE:GFP)* fish in the *yap1/wwtr1* heterozygous allele. Although we tried to incross the *yap1/wwtr1* heterozygous fish with the *Tg(BRE:GFP)* reporter, we could not get any viable embryos because the eggs were not fertilized. After many attempts, we concluded that our females were not fertile, possibly because of the presence of the *Tg(BRE:GFP)* transgene. Therefore, we alternatively investigated the downstream signaling of Bmp by performing immunostainings for phosphorylated Smad1/5/9 in *yap1/wwtr1* mutant, *lats1/2* mutant, and wild-type embryos (New Figure 6---figure supplement 1A). In the *yap1/wwtr1* double mutant embryos, phosphorylated Smad1/5/9 was decreased, while in the *lats1/2* double mutant embryos phosphorylated Smad1/5/9 was increased. These new data suggest that Hippo signaling in the ALPM suppresses Bmp signaling and confirm our previous conclusions.

In addition, following the reviewers' advice, we tried to investigate whether injection of *bmp2b* mRNA rescues the *yap1/wwtr1* mutant phenotypes. As *bmp2b* overexpression leads to ventralization, which is not compatible with the analysis of the *bmp2b* expression domain, we established the optimal concentration of *bmp2b* to inject in the embryo leading to significantly low ventralized phenotype. We found that 30% of the embryos showed the ventralized phenotype when using 1.5 pg of *bmp2b* (as shown in [Author response image 2](#respfig2){ref-type="fig"}). When injected in mutant embryos, we could not detect a clear rescue of the global *yap1/wwtr1* mutant morphology. Since the number of double mutants is only 1 out of 16, the number of embryos we could analyze was too low to directly assess the ALPM phenotype. Therefore, we could not draw definitive conclusions based on these experiments. This experiment requires a more complex approach such as tissue-specific expression of *bmp2b* in the ALPM using *gata4* or *nkx2.5* promoter in the double mutant. Unfortunately, providing these experiments in the time frame of the revision agreed with the editor is not possible since it requires the generation of new transgenic lines that are not available at the moment.

In light of the fact that *nkx2.5* expression is not altered in the *yap1/wwtr1* (as well as in the *lats1/2* morphants), we agree with the reviewers that our model needs adjustment. We have now changed the Discussion so that it is clear that it is possible that the expression of *nkx2.5* might be regulated by the Bmp signaling that is not downstream of the Hippo signaling. The fact that dorso-ventral axis formation is not solely dependent on the Yap1/Wwtr1-Bmp signaling supports the possibility for additional regulators of BMP signaling in the ALPM. Overall, we think our proposition that the Hippo signaling-dependent Bmp signaling acts through Hand2 expression to restrict ALPM cell fate to become venous pole cells is valid. The identity of pathways involved and their timing of action is an active line of research in the lab and will require more time to reach conclusions.

![Bright field images of the embryo injected with bmp2b mRNA (1.5 pg) and yap1ncv117wwtr1ncv114 embryo at 22 hpf.\
Lateral view, anterior to the left. bmp2b mRNA leads to ventralized phenotype (left panel). Yap1/wwtr1 mutant exhibits the defect of posterior body elongation (right panel).](elife-29106-resp-fig2){#respfig2}

> 3\) The phenotype shown for an embryo overexpressing smad7 mRNA does not seem to be a standard BMP-induced dorsalization phenotype, which is surprising. The appearance of the embryo in Figure 6--figure supplement 3A and the fragmented cells in Figure 6H suggest that the overexpression of smad7 may be causing cell death. Additionally, the cardiac phenotype attained after smad7 overexpression was not quantified, weakening the conclusions made from this experiment. If the authors intend to demonstrate cell-autonomous epistasis, they will likely need to use another approach. (Perhaps overexpression of a dominant-negative Bmp receptor?)

We sincerely apologize for the confusion. It is due to the fact that the phenotype we obtained was variable and chose to display the mild phenotype embryos to exemplify dorsalized phenotype in the embryos injected with *smad7* mRNA in the previous figure. We replaced the previous figure with a new supplemental figure (Figure 6---figure supplement 3A) showing a dorsalized embryo following the *smad7* mRNA Injection. We quantified again the percentage of dorsalized-phenotype and this time only embryos with phenotypes shown in Figure 6---figure supplement 3B were considered dorsalized embryos. The number of dorsalized embryos is decreased by comparison to the previous figure but this does not alter our conclusions that 100 pg is the best concentration to perform the overexpression experiment in the *Tg(isl1:GFP);Tg(myl7:Nls-mCherry)* embryos.

As suggested by the reviewers, we now provide a revised version where we quantified the number of *isl1*+ SHF cells in the embryo injected with *smad7* mRNA (new Figure 6F). While the number of *isl1*+ SHF cells was decreased by the injection of *smad7* mRNA, we could not detect any fragmented cells by confocal microscopy of the heart region highlighted by the *TgBAC(isl1:GFP);Tg(myl7:Nls-mCherry)* reporters at 26 hpf (see [Author response image 3](#respfig3){ref-type="fig"}). These results indicate that the decrease of the *isl1*+ SHF cells of the embryo injected with *smad7* mRNA was due to the inhibition of Bmp signaling and not cell fragmentation. These results are consistent with our previous results showing the decrease of the *isl1*+ SHF cells treated with the BMP inhibitor DMH1 (Figures 6I and 6J).

Following the reviewers' comment, we toned down our previous statement about cell- autonomous epistasis because Bmp is a secretory molecule and we cannot exclude non-cell autonomous regulation.

> 4\) In the experiment using DNA injection to induce mosaic Bmp2b expression (Figure 6---figure supplement 2A), the cells expressing bmp2b-2A-mCherry look fragmented, suggesting toxicity. The tissue on the left side also looks necrotic and the Yap1 reporter is very weak, while the authors state that it is unaffected. These results are not appropriate for inclusion in the manuscript. It is unclear why the authors did not use the available hsp70:bmp2b transgenic line to generate mosaic embryos through transplantation.

We agree with the reviewer that the cells look fragmented. We performed new experiments by imaging the bmp2b positive cells using confocal microscopy at high magnification and these experiments confirmed that a significant fraction of the cells expressing bmp2b-2A-mCherry is fragmented. We thank the reviewers for noticing this oversight. As the reviewers suggested, the data have been deleted from the revised version. We did not proceed further with this approach, we thus decided to delete the previous Figure 6C, 6D, and Figure 6---figure supplement 2A.

![The number of fragmented isl1 promoter-activated SHF cells of the embryos injected with the smad7 mRNA is very low as indicated at the bottom.\
The heart region was highlighted by the TgBAC(isl1:GFP);Tg(myl7:Nls-mCherry) embryos at 26 hpf (n=3).](elife-29106-resp-fig3){#respfig3}

Nevertheless, we strongly believe that our conclusions are still valid in absence of these experiments. Collectively, we now have the following data supporting our claim that Bmp2b is regulated by Hippo signaling to determine the number of SHF cells in the venous pole.

1\) The Hippo signaling pathway inhibits phosphorylation of Smad1/5/9 (New Figure 6---figure supplement 1A).

2\) The forced expression of *smad7* mRNA results in a decrease of SHF cells (New Figures 6E and 6F).

3\) DMH1 treatment leads to a decrease of SHF cells (Figures 6I and 6J).

4\) Both the activity of the Bmp reporter and the phosphorylation of Smad1/5/9 are increased in the venous pole (New Figures 6C, 6D, and Figure 6---figure supplement 2B).

Therefore, we feel confident that the data obtained by transient and mosaic expression of Bmp2b using Tol2 system are unnecessary to support our claim.

> 5\) In their revised manuscript, the authors conclude that venous pole cells originate on both sides of the ALPM, but they also state that \"more cells moved from the left ALPM to the venous pole compared to the cells coming from the right ALPM\". It is not clear that this semi-quantitative comparison is warranted, since it does not seem as if the authors tracked all of the cells on both sides of the ALPM. In Video 1, the authors compare five cells on the left to two cells on the right and state that this is representative of six independent experiments. How do the numbers compare among the six experiments? Is this a quantitatively reproducible observation? Do the photoconversion experiments (Figure 3D) reinforce the view that more venous pole cells come from the left than from the right? It is challenging to make a quantitative conclusion from this type of mosaic analysis. The authors should clarify the basis for this quantitative comparison between the left and right sides, or, alternatively, adjust their interpretation. Additionally, it would be helpful if the authors could clarify what criteria they used to define whether or not a tracked cell (or a photoconverted cell) became part of the venous pole in these experiments. Do the seven tracked cells in Video 1 account for the entirety of the venous pole?

We agree with the reviewers' comment that it is challenging to make quantitative conclusions about the proportion of cells coming from the left and right ALPM. We also agree that we cannot conclude about a potential bias between left and right contribution of ALPM cells into the SHF. It was a mistake on our side and we sincerely apologize for it. In fact, re-examining our data we find that the Tead reporter is bilaterally expressed equally between the two embryonic sides, which would be difficult to reconcile with our previous conclusion. Similarly, *bmp2b* expression is symmetrically altered in the *lats1/2* mutants and morphants. We thus feel that exploring the asymmetric contribution of ALPM cell to the SHF is not in the focus of our study and unnecessary. We, therefore, decided not to include this conclusion and changed the previous statement "the more cells in the left ALPM migrate toward the venous pole cells" into "*hand2* positive cells of venous pole differentiate from the caudal ALPM".

> 6\) The authors have revised their title and Abstract to accompany the changes to their model that they have incorporated into their revised manuscript. It may be beneficial to consider revising these further in order to better emphasize the key points that are most strongly supported by the current text. For example, the title claims that Hippo signaling \"suppresses the differentiation of cardiac precursor cells\" but it is not clear that suppression of differentiation is shown here. More venous pole cells are produced when Hippo signaling is inhibited, but it is not evident whether this occurs through alteration of differentiation (as opposed to alteration of specification or proliferation). To make this claim, the authors would need to provide additional data in support of this conclusion. Also, the authors emphasize that the activity of Hippo signaling occurs \"prior to establishment of the heart field\", but it is not clear what they mean by this phrase. When do they consider the heart field to be established, and what is the significance of its establishment as it relates to the conclusions of their manuscript? Overall, it would be more effective if the title and Abstract emphasized formation of the venous pole specifically, as that seems to be the focus of the manuscript.

We agree that the previous title, Abstract and model did not fully reflect our results as the editor pointed out. We changed the title and revised the Abstract in accordance with our results, which demonstrate the involvement of Hippo signaling in the LPM and subsequent venous pole formation. We agree that the involvement of Hippo signaling specifically in the heart field is not established in our study. Therefore, we changed the previous title into a more precise title with a focus on the venous pole specification. The new title is "Hippo signaling determines the number of atrial cells that originate from the anterior lateral plate mesoderm in zebrafish".

We also agree that the heart field was not well introduced leading to confusion about the origin of the additional cardiomyocytes observed in the Hippo pathway mutants. We rewrote extensively the Introduction and the Results to clarify this important issue.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The manuscript has been improved through its second round of revision, both by adding new data and by removing less convincing elements. Altogether, the revisions have streamlined and strengthened the overall clarity of the message regarding the impact of the Hippo signaling pathway on the number of venous pole cells in zebrafish, while toning down some of the more speculative or inconsistent aspects. However, there are some remaining issues that need to be addressed, as outlined below:
>
> 1\) With each revision of this manuscript, the authors have modified their title and Abstract to accompany the changes in their message. Further modification would help the current title to fit more closely with the main point of the paper, which revolves around the pathways regulating the number of venous pole (Isl1+) cells. The new title and Abstract seem to emphasize the whole atrium, even though the take-home message of the data is focused on the venous pole. Further adjustment is needed to align the title and Abstract with the rest of the manuscript.

We thank the editors and reviewers for the helpful suggestions. We changed the title and Abstract to focus on the venous pole as they pointed out. The new title is "Hippo signaling determines the number of venous pole cells that originate from the anterior lateral plate mesoderm in zebrafish". In the Abstract, we changed the final sentence to "Hippo signaling defines venous pole cardiomyocyte number by \[...\]" to focus on the venous pole.

> 2\) The data that are provided to argue that overexpression of smad7 (as in Figure 6) is non-toxic are not convincing. The authors have undertaken control experiments, examining whether embryos injected with smad7 mRNA look healthy, but this context is quite different from the mosaic scenario presented in the experiments, in which three different mRNAs are co-injected. It remains unexplored whether this cocktail is causing cell death (and therefore loss of hand2 expression) and therefore no conclusion can be drawn from this experiment. Therefore, the experiments utilizing smad7 overexpression should be removed from the manuscript.

Following the comments, to avoid the ambiguity of our results, we deleted the mosaic experiment results (Former Figure 6 G and H). Therefore, we renewed Figure 6.

> 3\) It appears premature for the authors to conclude a direct, linear relationship connecting Hippo signaling, Bmp signaling, and Hand2 expression. Without a formal epistasis experiment (e.g. DMH1 treatment in lats1/2 LOF and measuring the hand2 response), it does not seem appropriate to suggest this hierarchy. The most appropriate representation would be to conclude that Hippo signaling acts on both Bmp signaling and Hand2 expression. These could be independent influences, or they could be linked, but the data do not clearly support the direct linkage.

We agree with the reviewer's comment. We cannot exclude the possibility that Hippo signaling directly regulates hand2 expression and cannot conclude that hand2 is downstream of Bmp2 signaling. Therefore, we added a sentence to clarify this in the Discussion and edited Figure 7. In the new Figure 7, the two arrows denote the possibility that Hippo signaling acts on both Bmp signaling and Hand2.

> 4\) The authors should look through the manuscript carefully, as there are a number of errors in the text. Some examples, spotted by reviewers, are listed here:
>
> \- Instances where \"specification\" is used, when differentiation is appropriate
>
> \- \"compared to humans\" would read better as \"compared to mouse and humans\", given it follows a description of mice
>
> \- \"transcriptional factor\" should read \"transcription factor\"
>
> \- \"restricts determines\" is tautological and needs altering
>
> \- \"frameshifts\" should read \"frameshift mutations\"
>
> *- \"faithfully recapitulates isl1 expression* in vivo\" is an overstatement if all isl1 expression was not assessed.
>
> \- "Interestingly, the gap length of WT embryos was significantly shorter than that of the lats1wt/ncv107lats2ncv108 embryos, the lats1/2 DKO embryos and the lats1/2 morphants." However, the data in Figure 5 shows that gap length in wt embryos is larger.

We thank the reviewers/editors for listing up our mistakes in the manuscript. We carefully checked the manuscript including the mistakes listed up and corrected other grammatical errors.

> 5\) It would be beneficial for the authors to review their choices of cited articles. In some cases, it seems as if the citations may not be the best choices to fully support the statements made. For example, does Hami et al. (2011) strongly support the points for which it is cited in the Introduction (that SHF cells come from the lateral and caudal ALPM, and that Isl1+ cells give rise to the inflow tract)?

According to the reviewers/editors' comments, we checked whether the citations match our statements. When we found the best manuscript that fit our description, we replaced previous citations with new citations.
